PATRONAGES

European League Against the Rheumatism (EULAR)

Italian Society of Rheumatology
(Società Italiana di Reumatologia – SiR)

ERN ReCONNET

The University Of Genoa

The Department of internal medicine and medical specialities (DiMI)
University of Genoa

The Region Liguria

The IRCCS Polyclinic Hospital San Martino Genoa

The Metropolitan City of Genoa

The City of Genoa
From at least 2,000 years the Mediterranean area with the connected Black and Red Sea populations has been the “CRIB” of the culture, science and good life.

What means good life?

What means good life? Good life mean an acceptable style of life, even modest but healthy, and of course, it includes good food and good climate! Today, we recognize that, among the multiple risk factors involved in the development of several diseases, environmental and nutritional components play an important role. The rheumatic diseases are among the most common diseases in the general population and the effects of wrong diets and non-healthy environment/style of life, are recognized as important promoters for their development. Correct diet represents also part of a correct management of the Rheumatic & Musculoskeletal Diseases. Already from the beginning, the Mediterranean Congress of Rheumatology has presented the experiences regarding the characteristics of the Rheumatic Diseases in such area, and comparing their epidemiology among the European countries. This 2018 edition of the Congress will focus about the effects of the diet and the climate on the most frequent Rheumatic and Musculoskeletal Diseases, including their early diagnosis and advanced therapies. The Congress topics will be discussed in sequential sessions and will include appropriate presentations on nutritional and environmental factors that will integrate the clinical and drug treatment lectures. Of course, participants will have the occasion to taste personally in spring time, the therapeutical effects of the Mediterranean diet and climate “available” for all participants during the Congress that will be held in the Old Harbor of Genoa.
**INTERNATIONAL ADVISORS**

<table>
<thead>
<tr>
<th>Advisor</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Akkoc</td>
<td>Izmir, Turkey</td>
</tr>
<tr>
<td>S. Aligrutic</td>
<td>Podgorica, Montenegro</td>
</tr>
<tr>
<td>A. Alunno</td>
<td>Perugia, Italy</td>
</tr>
<tr>
<td>B. Anic</td>
<td>Zagreb, Croatia</td>
</tr>
<tr>
<td>S. Ataman</td>
<td>Ankara, Turkey</td>
</tr>
<tr>
<td>M. Reda Awad</td>
<td>Agouza, Giza, Egypt</td>
</tr>
<tr>
<td>H. Bassiouni</td>
<td>Cairo, Egypt</td>
</tr>
<tr>
<td>S. Bombardieri</td>
<td>Pisa, Italy</td>
</tr>
<tr>
<td>J.W.J. Bijlsma</td>
<td>Utrecht, The Netherlands</td>
</tr>
<tr>
<td>D. Boumpas</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>G.R. Burmester</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>L. Carmona</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>C. Christodoulou</td>
<td>Larnaca, Cyprus</td>
</tr>
<tr>
<td>B. Coleiro</td>
<td>Birkirkara, Malta</td>
</tr>
<tr>
<td>B. Combe</td>
<td>Montpellier, France</td>
</tr>
<tr>
<td>J.A.P. Da Silva</td>
<td>Coimbra, Portugal</td>
</tr>
<tr>
<td>N. Damjanov</td>
<td>Belgrade, Serbia</td>
</tr>
<tr>
<td>L. Denisov</td>
<td>Moscow, Russia</td>
</tr>
<tr>
<td>A. Dinc</td>
<td>Çankaya, Turkey</td>
</tr>
<tr>
<td>H. Direshkeneli</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>A. Doria</td>
<td>Padua, Italy</td>
</tr>
<tr>
<td>A. El Garf</td>
<td>Cairo, Egypt</td>
</tr>
<tr>
<td>O. Elkayam</td>
<td>Tel Aviv, Israel</td>
</tr>
<tr>
<td>K. Elmuntaser</td>
<td>Tripoli, Libya</td>
</tr>
<tr>
<td>J.E. Fonseca</td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td>M. Gattorno</td>
<td>Genoa, Italy</td>
</tr>
<tr>
<td>S. Grazio</td>
<td>Zagreb, Croatia</td>
</tr>
<tr>
<td>A. Gul</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>N. Hajjaj-Hassouni</td>
<td>Rabat, Morocco</td>
</tr>
<tr>
<td>I. Holc</td>
<td>Maribor, Slovenia</td>
</tr>
<tr>
<td>A. Iagnocco</td>
<td>Turin, Italy</td>
</tr>
<tr>
<td>M. Inanc</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>R. Ionescu</td>
<td>Bucharest, Romania</td>
</tr>
<tr>
<td>L. Kazzaz</td>
<td>Damascus, Syria</td>
</tr>
<tr>
<td>G.D. Kitas</td>
<td>Manchester, UK</td>
</tr>
<tr>
<td>M. Kou lou mas</td>
<td>Nicosia, Cyprus</td>
</tr>
<tr>
<td>E. J. Kucharz</td>
<td>Katowice, Poland</td>
</tr>
<tr>
<td>A. Ladjouze</td>
<td>Algiers, Algeria</td>
</tr>
<tr>
<td>C. Mallia</td>
<td>Msida, Malta</td>
</tr>
<tr>
<td>X. Mariette</td>
<td>Paris, France</td>
</tr>
<tr>
<td>A. Martini</td>
<td>Genoa, Italy</td>
</tr>
<tr>
<td>M. Matucci Cerinic</td>
<td>Florence, Italy</td>
</tr>
<tr>
<td>I. McInnes</td>
<td>Glasgow, UK</td>
</tr>
<tr>
<td>G. Minisola</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>P. Miossec</td>
<td>Lyon, France</td>
</tr>
<tr>
<td>S. Mishevska-Percinkova</td>
<td>Skopje, Republic of Macedonia</td>
</tr>
<tr>
<td>C. Montecucco</td>
<td>Pavia, Italy</td>
</tr>
<tr>
<td>M. Mosca</td>
<td>Pisa, Italy</td>
</tr>
<tr>
<td>E. Nasonov</td>
<td>Moscow, Russia</td>
</tr>
<tr>
<td>E. Nikiphorou</td>
<td>London, UK</td>
</tr>
<tr>
<td>C.H. Opava</td>
<td>Huddinge, Sweden</td>
</tr>
<tr>
<td>N. Prodanovic</td>
<td>Banja Luka, Republic of Srpska - Bosnia Herzegovina</td>
</tr>
<tr>
<td>R. Rashkov</td>
<td>Sofia, Bulgaria</td>
</tr>
<tr>
<td>A. Ravelli</td>
<td>Genoa, Italy</td>
</tr>
<tr>
<td>P. Sarzi Puttini</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>J. Sellam</td>
<td>Paris, France</td>
</tr>
<tr>
<td>P. Sfikakis</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>Y. Shoenfeld</td>
<td>Tel Aviv, Israel</td>
</tr>
<tr>
<td>V. Smith</td>
<td>Ghent, Belgium</td>
</tr>
<tr>
<td>S. Sokolovic</td>
<td>Sarajevo, Bosnia and Herzegovina</td>
</tr>
<tr>
<td>R. Straub</td>
<td>Regensburg, Germany</td>
</tr>
<tr>
<td>S.G. Sukkar</td>
<td>Genoa, Italy</td>
</tr>
<tr>
<td>Z. Szekanecz</td>
<td>Debrecen, Hungary</td>
</tr>
<tr>
<td>A. Tafaj</td>
<td>Tirana, Albania</td>
</tr>
<tr>
<td>M. Tishler</td>
<td>Zrifin, Israel</td>
</tr>
<tr>
<td>A. Tzioufas</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>I. Uthman</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>D. Wiek</td>
<td>Hünxe, Germany</td>
</tr>
<tr>
<td>H. Yazici</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>D. Vassilopoulos</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>L. Zakraoui</td>
<td>Tunis, Tunisia</td>
</tr>
</tbody>
</table>
**NATIONAL ADVISORS**

S. Antonelli  Rome, Italy  
G. Arioli  Mantua, Italy  
G. Bajocchi  Reggio Emilia, Italy  
M. Bentivegna  Ragusa, Italy  
R. Caporali  Pavia, Italy  
S. D’Angelo  Potenza, Italy  
L. Di Matteo  Pescara, Italy  
M. Galeazzi  Siena, Italy  
R. Gerli  Perugia, Italy  

A. Mathieu  Cagliari, Italy  
I. Olivieri †  Potenza, Italy  
L. Quartuccio  Udine, Italy  
F. Salaffi  Ancona, Italy  
G. Sebastiani  Rome, Italy  
L. Sinigaglia  Milan, Italy  
A. Tincani  Brescia, Italy  
G. Valesini  Rome, Italy  

**LOCAL ADVISORS**

P. Comanducci  Rector University of Genoa  
M. Amore  Dean School of Medicine University of Genoa  
G. Ucci  CEO of the Polyclinic Hospital San Martino  
G. La Valle  Chief Medical Officer of the Polyclinic Hospital San Martino  
S. Viale  CEO Health System & Vice President of Liguria Government  
M. Bucci  Major of the City of Genoa  
S. Balleari  Vice Major of the City of Genoa  

P. Odetti  Director Medical Department - DiMI - University of Genoa  
S.G. Sukkar  Director Clinical Nutrition Polyclinic Hospital San Martino  
S. Ferrero  Congress Medical Link Officer at the Liguria Government  
M. Cutolo  Director Division of Rheumatology – DiMI  

**MEDICAL TEAM**

Division of Rheumatology – DiMI  
University of Genoa  
A. Sulli  
S. Paolino  
C. Pizzorni  
M. Ghio  
B. Ruaro  
M.A Cimmino
**PRELIMINARY TIMETABLE**

### Thursday 12th April, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>PLATEA MAESTRALE ROOM</th>
<th>LEVANTE-PONENTE ROOM</th>
<th>LIBECCIO ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Opening Registrations and Exhibition</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>OPENING CEREMONY</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>LECTURE</td>
<td>The diet in rheumatic autoimmune diseases: a recipe for therapy?</td>
<td></td>
</tr>
<tr>
<td>14:30-15:15</td>
<td>LECTURE</td>
<td>Early Rheumatoid Arthritis</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>LECTURE</td>
<td>Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?</td>
<td></td>
</tr>
<tr>
<td>15:30-16:15</td>
<td>LECTURE</td>
<td>Epigenetic Effects of the Mediterranean Diet</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>START THE POSTER EXHIBITION</td>
<td>NOT ACCREDITED</td>
<td></td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>SECOND SESSION</td>
<td>Gouty Arthritis and dismetabolism</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>LECTURE</td>
<td>Metabolic effects of Glucocorticoids: is there a safe dosage?</td>
<td></td>
</tr>
<tr>
<td>18:00-19:00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Friday 13th April, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>PLATEA MAESTRALE ROOM</th>
<th>LEVANTE-PONENTE ROOM</th>
<th>LIBECCIO ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>THIRD SESSION</td>
<td>Osteoarthritis and its management</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>10:30-11:15</td>
<td>FOURTH SESSION</td>
<td>Autoinflammatory and Rare Connective Tissue Diseases</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-11:55</td>
<td>Industry - Sponsored</td>
<td>Satellite Lecture</td>
<td>NOT ACCREDITED</td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Industry - Sponsored</td>
<td>Satellite Symposium</td>
<td>NOT ACCREDITED</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>POSTER TOUR</td>
<td>NOT ACCREDITED</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PRELIMINARY SCIENTIFIC PROGRAM

Friday 13th April, 2018 – afternoon

<table>
<thead>
<tr>
<th>Time</th>
<th>Platea Maestrale Room</th>
<th>Levante-Ponente Room</th>
<th>Doccia Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30-10.30</td>
<td>LECTURE: Sun, vitamin D and rheumatic diseases</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>10.30-11.30</td>
<td>Fostering physical activity together with correct nutrition, a win-win approach but rarely respected in RMDs</td>
<td>FIFTH SESSION: From Raynaud’s phenomenon up to Systemic Sclerosis</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>LECTURE: Biocertisphere and RMDs: when, where and how to choose</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>12.00-13.00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-15.00</td>
<td>SIXTH SESSION: Systemic Lupus Erythematosus and related syndromes</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
</tbody>
</table>

Saturday 14th April, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Platea Maestrale Room</th>
<th>Levante-Ponente Room</th>
<th>Doccia Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30-10.30</td>
<td>SEVENTH SESSION: Spondyloarthritis and Psoriatic Arthritis</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>10.30-11.30</td>
<td>EIGHTH SESSION: Osteoporosis and lifestyle</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-12.50</td>
<td>NINTH SESSION: Sjogren syndrome today</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>13.00-13.20</td>
<td></td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>13.30-14.30</td>
<td>CLOSING REMARKS</td>
<td>related ORAL COMMUNICATIONS</td>
<td>related ORAL COMMUNICATIONS</td>
</tr>
</tbody>
</table>

*Further variations should be expected before the Congress

We invite all Congress participants to attend the seven Lectures which will be held during Thursday 12 April and Friday 13 April, 2018.
Nine Scientific Sessions and related Oral communications will be held over the three days. Other interesting Sessions dedicated to Patients will take place between Friday and Saturday; a Pediatric Session on Friday, as well the SPECIAL Ultrasound Session will run in parallel to the other Scientific Sessions on Saturday.
Industry - Sponsored Satellite Lectures and Satellite Symposia will occupy the slots from 11.20 to 12.50 on Friday 13 April, 2018.
Poster Exhibition and Tour are planned before afternoon Coffee break on Thursday 12 April and before lunch on Friday 13 April.
IMPORTANT NOTICE for Scientific Sessions

We invite all Congress participants to attend the nine Scientific Sessions which will be held during Thursday 12, Friday 13 and Saturday 14 April, 2018 into the “Platea Maestrale” Room. Each Session will focus on the priority themes listed below. In parallel with each Session will correspond the related Oral Communication Session.

- Epidemiology, nutritional aspects and environmental factors
- The early disease: clinical features and diagnostic tools
- Management: from guidelines up to the last treatment issues
- Management: non pharmacological aspects and unmet needs

The speeches which differ from the above mentioned titles and thematic are indicated in the following Program.

Thursday, April 12th 2018

13.30 – 14.00 Platea Maestrale Room

**OPENING CEREMONY**
Welcome from Local Academic, Hospital and Government Authorities

14.00 – 14.30 Platea Maestrale Room

**LECTURE - The diet in rheumatic autoimmune diseases: a recipe for therapy?**

*Speaker:*
**Y. Shoenfeld** *(Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel; Head of the Mosaic of Autoimmunity Project, Saint Petersburg State University)*

*Chair:*
**M. Cutolo** *(Genoa, Italy)*

14.30 - 15.40 Platea Maestrale Room

**FIRST SESSION: Early Rheumatoid Arthritis**

*Speakers:*
14.30 Epidemiology, nutritional aspects and environmental factors
   **I. McInnes** *(Glasgow, UK)*
14.45 The early disease: clinical features and diagnostic tools
   **G. Burmester** *(Berlin, Germany)*
15.00 Management: from guidelines up to the last treatment issues
   **B. Combe** *(Montpellier, France)*
15.15 Management: non pharmacological aspects and unmet needs
   **Z. Szekanecz** *(Debrecen, Hungary)*

*Chairs:*
**G. Burmester** *(Berlin, Germany), C. Montecucco** *(Pavia, Italy)*
14.30 - 15.40  Levante – Ponente Room

FIRST SESSION: Early Rheumatoid Arthritis
Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC1:1  VACCINATIONS IN INFLAMMATORY ARTHRITIS PATIENTS
       S. Khan (Dublin, Ireland)

OC1:2  MULTICENTER CROSS-SECTIONAL STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS IN GREECE. RESULTS FROM A COHORT OF 2,491 PATIENTS
       K. Thomas (Athens, Greece)

OC1:3  THE ROLE OF DIET ON RHEUMATOID ARTHRITIS: WHAT DO CLINICAL TRIALS TELL US?
       S. Petersson (Nicosia, Cyprus)

OC1:4  FACTORS ASSOCIATED WITH PROGRESSION TO INFLAMMATORY ARTHRITIS IN THE FIRST-DEGREE RELATIVES (FDR) OF INDIGENOUS NORTH AMERICAN (INA) RA PATIENTS
       H. EL-Gabalawy (Winnipeg, Canada)

OC1:5  SALT CONSUMPTION MAY BE A RISK FACTOR FOR THE DEVELOPMENT OF ARTHRITIS
       L. Carmona (Madrid, Spain)

OC1:6  DIETETIC THERAPY AND RHEUMATOID ARTHRITIS
       L. Denisov (Moscow, Russia)

Chair – INTRODUCTION:
R. Caporali (Pavia, Italy)

15.40 – 16.10  Platea Maestrale Room

LECTURE - Mediterranean Diet in the 3rd Millennium: Just Prevention or even Therapy?
Speaker:
A. Trichopoulou (Athens, Greece)
Chair:
S.G. Sukkar (Genoa, Italy)

16.10 – 16.40  Platea Maestrale Room

LECTURE - Epigenetic Effects of the Mediterranean Diet
Speaker:
A. Martinez (Pamplona, Spain)
Chair:
S.G. Sukkar (Genoa, Italy)

16.40 – 17.10  Poster Area  NO CME ACTIVITY

START THE POSTER EXHIBITION

16.40 – 17.10  Poster and Exhibition Area  Coffee break
Thursday, April 12th 2018

17.10 - 18.20  Platea Maestrale Room

SECOND SESSION: Gouty arthritis and dismetabolism

Speakers:
17.10  Nutritional aspects - including weight loss - for gout: an update from clinical epidemiology
S. M. Nielsen (Copenhagen, Denmark)
17.25  The early disease: clinical features and diagnostic tools
F. Sivera (Alicante, Spain)
17.40  Management: from guidelines up to the last treatment issues
P. Richette (Paris, France)
17.55  Management: non pharmacological aspects and unmet needs
L. Punzi (Padua, Italy)

Chairs:
L. Punzi (Padua, Italy), P. Richette (Paris, France)

17.10 - 18.20  Levante – Ponente Room

SECOND SESSION: Gouty arthritis and dismetabolism
Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:
OC2:1  EFFECT OF POLYDATIN AND RESVERATROL ON CRYSTAL-INDUCED INFLAMMATION: BENEFICIAL IMPLICATIONS FOR GOUT AND OTHER CRYSTAL-RELATED ARTHROPATHIES
F. Oliviero (Padua, Italy)
OC2:2  ANALYSIS OF THE EFFICACY OF LOW PURINE DIET IN GOUT PATIENTS
M.S. Eliseev (Moscow, Russia)
OC2:3  COMBINATION OF LOSARTAN AND ALLOPURINOL IN HYPERTENSIVE PATIENTS WITH HYPERURICEMIA
M. Jordhani (Tirana, Albania)
OC2:4  ULTRA-LOW DOSE ANTI-INTERLEUKIN1 IN CHRONIC GOUT: A SAFE AND SUCCESSFUL COMBINATION THERAPY WITH LOW DOSE COLCHICINE AND URATE LOWERING AGENTS
M. Capassoni (Florence, Italy)
OC2:5  SEASONAL VARIATION OF JOINT ASPIRATIONS FOR GOUT AND CPPD IN A COHORT OF ARTROPATHIC PATIENTS WITH EFFUSION
M.A. Cimmino (Genoa, Italy)
OC2:6  GOUT AND METABOLIC SYNDROME
N. Zehraoui (Algiers, Algeria)

Chair – INTRODUCTION:
S. Grazio (Zagreb, Croatia)

18.20 – 18.50  Platea Maestrale Room

LECTURE - Metabolic effects of Glucocorticoids: is there a safe dosage?

Speaker:
J.W.J. Bijlsma (Utrecht, The Netherlands)

Chair:
M. Cutolo (Genoa, Italy)
Friday, April 13th 2018

8.30 - 9.40 Platea Maestrale Room

**THIRD SESSION: Osteoarthritis and its management**

**Speakers:**

8.30  
Epidemiology, nutritional aspects and environmental factors  
*C. Scire* (Ferrara, Italy)

8.45  
The early disease: new aspects on the role of imaging  
*A. Iagnocco* (Turin, Italy)

9.00  
Management: from guidelines up to the last treatment issues  
*J.Y Reginster* (Liège, Belgium)

9.15  
Management: non pharmacological aspects and unmet needs  
*P. Sarzi-Puttini* (Milan, Italy)

**Chairs:**

*M. Galeazzi* (Siena, Italy), *J.Y. Reginster* (Liège, Belgium)

8.30 - 9.40 Levante – Ponente Room

**THIRD SESSION: Osteoarthritis and its management**

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**Oral Communications:**

OC3:1  
MUTUAL INTERACTION BETWEEN OXIDATIVE STRESS AND MICRORNAS. AN IN VITRO STUDY ON HUMAN OSTEARTHRITIC CHONDROCYTE CULTURES  
*S. Cheleschi* (Siena, Italy)

OC3:2  
KNEE ARTHRITIS AND METABOLIC SYNDROM  
*D. Dusa* (Constanta, Romania)

OC3:3  
VISCOSUPPLEMENTATION IN NON-SEVERE KNEE OSTEOARTHRITIS: A NETWORK META-ANALYSIS OF HIGH QUALITY RANDOMIZED CLINICAL TRIALS  
*L. Carmona* (Madrid, Spain)

OC3:4  
MUD-BATH THERAPY REGULATES THE EXPRESSION LEVELS OF MICRORNAS IN OSTEOARTHRITIS. EPIGENETIC CONTRIBUTION TO EXPLAIN THE MECHANISM OF ACTION OF BALNEOTHERAPY  
*S. Cheleschi* (Siena, Italy)

OC3:5  
PATIENTS PERCEPTION OF PAIN IN OSTEOARTHRITIS: RESULTS OF A ROUMANIAN SURVEY  
*I. Saulescu* (Bucharest, Romania)

OC3:6  
KNEE EXTENSOR MUSCLE WEAKNESS AND RADIOGRAPHIC KNEE OSTEOARTHRITIS PROGRESSION  
*A. Dell'isola* (Glasgow, United Kingdom), (Savona, Italy)

**Chair – INTRODUCTION:**

*G. Sebastiani* (Rome, Italy)

8.30 – 09.40 Libeccio Room

**Pediatric Rheumatology in the Mediterranean area**

Concomitant Session

**Speakers:**

08.30  
Multinational Study on epidemiology, treatment and outcome of children with idiopathic juvenile arthritis  
*A. Ravelli* (Genoa, Italy)
Friday, April 13th  2018

09.00  Longitudinal evaluation of growth and puberty development in pediatric rheumatic diseases
        **N. Ruperto** (Genoa, Italy)

09.40  Discussion

Chairs:
        **A. Martini** (Genoa, Italy), **A. Ravelli** (Genoa, Italy)

9.40 – 10.50  Platea Maestrale Room

**FOURTH SESSION: Autoinflammatory and Rare Connective Tissue Diseases**

Speakers:
9.40  Autoinflammatory diseases: diagnostic criteria, guidelines and advances
        **M. Gattorno** (Genoa, Italy)

9.55  Focus on familial Mediterranean fever
        **H. Lachmann** (London, UK)

10.10 Beyond for the vasculitis risk in the Mediterranean
        **A. Gul** (Istanbul, Turkey)

10.25 Focus on Behçet disease
        **L. Cantarini** (Siena, Italy)

10.40 NEWS – 5 minutes Short report on a new European Project- ERN, on Rare Connective Tissue Diseases – ReCONNET
        **M. Mosca** (Pisa, Italy)

Chairs:
        **M. Gattorno** (Genoa, Italy), **H. Lachmann** (London, UK)

9.40 – 10.50  Levante – Ponente Room

**FOURTH SESSION: Autoinflammatory and Rare Connective Tissue Diseases**

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC4:1  A GENETIC COHORT STUDY TO GENOTYPE SEVERAL INTERLEUKIN GENE POLYMORPHISMS IN A GROUP OF BEHÇET’S SYNDROME PATIENTS LIVING IN THE MEDITERRANEAN AREA
        **M.C. Padula** (Potenza, Italy)

OC4:2  ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IN
        **M.L. Popescu** (Bucharest, Romania)

OC4:3  CAN AUTOANTIBODIES PREDICT OUTCOMES OR SURVIVAL IN INTERSTITIAL LUNG DISEASE?: RESULTS FROM A RETROSPECTIVE COHORT STUDY IN GREECE.
        **A. Venetsanopoulou** (Athens, Greece)

OC4:4  BIRMINGHAM VASCULITIS ACTIVITY INDEX (BVAS) A USEFUL TOOL IN DISEASE ACTIVITY IN BEHÇET’S DISEASE
        **C. Buzatu** (Bucharest, Romania)

OC4:5  A SEASONAL ONSET FOR POLYMYALGIA RHEUMATICA?
        **E. Hysa** (Genoa, Italy)

OC4:6  ASSESSMENT OF ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESSMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS
        **M. Inanc** (Istanbul, Turkey)

Chair – **INTRODUCTION:**
        **M. Inanc** (Istanbul, Turkey)
PATIENT SESSION:
Pregnancy in RMDs: what the patients would like to know

SESSIONE DEDICATA AI PAZIENTI: Gravidanza e malattie reumatiche: quello che il malato vorrebbe sapere

Concomitant Session

Speakers:

LECTURE: Pregnancy yes in RMDs
A. Tincani (Brescia, Italy)

LECTURE: Lettura: Pregnancy No in RMDs
L. Andreoli (Brescia, Italy)

Chair:
A. Tincani (Brescia, Italy)

10.50 – 11.20
Poster and Exhibition Area
Coffee break

11.20 – 11.50
Platea Maestrale Room / Levante – Ponente Room
Concomitants Industry - Sponsored SATELLITE LECTURES

11.50 – 12.50
Platea Maestrale Room / Levante – Ponente Room
Concomitants Industry - Sponsored SATELLITE SYMPOSIA

12.50 – 14.00
Poster Area
POSTER TOUR*

13.00 – 14.00
Poster and Exhibition Area
Lunch

14.00 -14.30
Platea Maestrale Room
LECTURE - Sun, vitamin D and rheumatic diseases
Speaker:
M. Cutolo (Genoa, Italy)

Chair:
G. Minisola (Rome, Italy)

14.00 – 16.40
Libeccio Room
YOUNG PATIENTS AND RHEUMATOLOGISTS SESSION:
The impact of nutrition and lifestyle on RMDS
Concomitant Session

Speakers:

14.00
People’s perceptions on nutritional aspects and rheumatic disease:
Completion of the “Truth or myth” questionnaire by the audience

14.10
Nutrition and rheumatic disease: are we really what we eat?
E. Philippou (Nicosia, Cyprus – London, UK)
Friday, April 13th 2018

14.30  The sun and rheumatic disease: friend or foe?
   **M. Cutolo** (Genoa, Italy)

14.50  The impact of diet in rheumatic diseases
   **C. Daien** (Montpellier, France)

15.10  Analysis and sharing of the results of the “Truth or myth” questionnaire at the end of the Session

15.20  ‘Your 5-a-day’ VIDEO for a healthy and ‘joint-friendly’ exercise regime that can be undertaken as part of the daily routine
   **L. Bacoccoli** - Personal trainer Virgin Active Village (Perugia, Italy)

15.30  Workshop – Problem based cases and discussion (Participants will be divided in groups)
   **M. Kouloumas** (Nicosia, Cyprus), **D. Wiek** (Hünxe, Germany)

Chairs: **A. Alunno** (Perugia, Italy), **M. Kouloumas** (Nicosia, Cyprus), **E. Nikiphorou** (London, UK), **D. Wiek** (Hünxe, Germany)

14.30 – 15.00  Platea Maestrale Room

**LECTURE** - Fostering physical activity together with correct nutrition: a successful approach but rarely respected in RMDs

Speaker: **G.D. Kitas** (Manchester, UK)

Chair: **S. Bombardieri** (Pisa, Italy)

15.00 – 16.10  Platea Maestrale Room

**FIFTH SESSION: From Raynaud’s phenomenon up to Systemic Sclerosis**

Speakers:

15.00  Epidemiology, nutritional aspects and environmental factors
   **U. Muller-Lardner** (Bad Nauheim, Germany)

15.15  The early disease: clinical features and diagnostic tools
   **M. Matucci Cerinic** (Florence, Italy)

15.30  Management: from guidelines up to the last treatment issues
   **C. Denton** (London, UK)

15.45  Management: non pharmacological aspects and unmet needs
   **O. Distler** (Zurich, Switzerland)

Chairs:
   **C. Denton** (London, Uk), **V. Smith** (Ghent, Belgium)

15.00 – 16.10  Levante – Ponente Room

**FIFTH SESSION: From Raynaud’s phenomenon up to Systemic Sclerosis**

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**Oral Communications:**

**OC5:1** ASSOCIATION OF INTERLEUKIN-17 AND INTERLEUKIN-23 MRNA AND PROTEIN EXPRESSION PROFILES WITH CLINICAL PRESENTATION IN PATIENTS WITH SYSTEMIC SCLEROSIS
   **A. Zekovic** (Belgrade, Serbia)
VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS: CORRELATIONS WITH MULTIPLE CLINICAL PARAMETERS, SEASONAL VARIATIONS AND TREATMENT EFFECTIVENESS IN EUROPEAN SSC PATIENTS

A.C. Trombetta (Genoa, Italy)

TYPE I INTERFERON INDUCED GENE EXPRESSION IN THE PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS

N. Vlachogiannis (Athens, Greece)

CORRELATIONS BETWEEN SKIN BLOOD PERFUSION AND CHOROIDAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS BEFORE AND AFTER A SHORT TIME TREATMENT WITH PROSTACYCLIN ANALOGUE

A. Sulli (Genoa, Italy)

RELIABILITY OF SIMPLE CAPILLAROSCOPIC DEFINITIONS TO DESCRIBE CAPILLARY MORPHOLOGY IN RHEUMATIC DISEASES

A. Vanhaecke (Ghent, Belgium)

MACITENTAN CONTRASTS THE ACTIVATION OF PROFIBROTIC INTRACELLULAR SIGNALING PATHWAYS INDUCED BY ENDOTHELIN-1 IN PRIMARY CULTURES OF SKIN FIBROBLASTS ISOLATED FROM HEALTHY SUBJECTS

S. Soldano (Genoa, Italy)

Chair – INTRODUCTION:
A. Sulli (Genoa, Italy)

16.10 – 16.40 Platea Maestrale Room

LECTURE - Balneotherapy and RMDs: when, where and how to choose
Speaker:
A. Fioravanti (Siena, Italy)
Chair:
T. Bender (Budapest, Hungary)

16.40 – 17.10 Poster and Exhibition Area

Coffee break

17.10 – 18.30 Platea Maestrale Room

SIXTH SESSION: Systemic Lupus Erythematosus and related syndromes

Speakers:
17.10 Epidemiology, nutritional aspects and environmental factors
G. Bertsias (Heraklion - Crete, Greece)

17.25 The early disease: clinical features and diagnostic investigations
D. Boumpas (Athens, Greece)

17.40 Management: from guidelines up to the last treatment issues
A. Doria (Padua, Italy)

18.00 The antiphospholipid syndrome: news on management and unmet needs
A. Tincani (Brescia, Italy)

Chairs:
D. Boumpas (Athens, Greece), M. Mosca (Pisa, Italy)
SIXTH SESSION: Systemic Lupus Erythematosus and related syndromes

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC6:1 TRANSCRIPTIONAL REGULATION OF BAFF-R, BCMA AND TACI BY MIR-873 AND MIR-1976 IN JUVENILE SLE
N.N Farag (Cairo, Egypt)

OC6:2 THROMBOSPONDIN-1 IS ELEVATED IN THE PLASMA OF PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND IS CORRELATED WITH FREE ACTIVE TGF-B1 LEVELS, IL-1B AND IL-17A
P. Vlachoyiannopoulos (Athens, Greece)

OC6:3 HYDROXYCHLOROQUINE DOSING: DOES BY IDEAL BODY WEIGHT OR GROSS WEIGHT MAKE A DIFFERENCE?
H.S.E. Fung (Waco, Texas-Usa)

OC6:4 AVEMAR, A NEW BENZOQUINONE CONTAINING NATURAL PRODUCT IN SLE PATIENTS TREATMENT
S.G. Sukkar (Genoa, Italy)

OC6:5 ANTIPHOSPHOLIPID SYNDROME: REVIEW OF 52 CASES OF A PORTUGUESE RHEUMATOLOGY DEPARTMENT
F. Campos Costa (Coimbra, Portugal)

OC6:6 OUTCOME OF ADULT PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND JUVENILE IDIOPATHIC ARTHRITIS IN A SINGLE COHORT
S. Al-Mayouf (Riyadh, Saudi Arabia)

Chair – INTRODUCTION:
P. Miossec (Lyon, France)

Open Questions to the Physician Nutritionist and to the Dietician

SESSIONE DEDICATA AI PAZIENTI:
Domande libere al Medico nutrizionista ed alla Dietologa

Concomitant Session

Chairs:
R. Gradaschi (Genoa, Italy), S.G. Sukkar (Genoa, Italy)
Saturday, April 14th 2018

8.30 – 9.40 Platea Maestrale Room

SEVENTH SESSION: Spondyloarthritis and Psoriatic Arthritis

Speakers:
8.30 Epidemiology, nutritional aspects and environmental factors
   R. Lories (Leuven, Belgium)
8.45 The early disease: clinical features and diagnostic tools
   I.E. Van der Horst-Bruinsma (Amsterdam, The Netherlands)
9.00 Management: from guidelines up to the last treatment issues
   R. Ramonda (Padua, Italy)
9.15 Management: non pharmacological aspects and unmet needs
   F. Ciccia (Palermo, Italy)

Chairs:
S. D’Angelo (Potenza - Matera, Italy), R. Lories (Leuven, Belgium)

8.30 – 9.40 Levante – Ponente Room

SEVENTH SESSION: Spondyloarthritis and Psoriatic Arthritis

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

Oral Communications:

OC7:1 METABOLIC SYNDROME, NON ALCOHOLIC FATTY LIVER DISEASE AND LIVER STIFFNESS IN PSORIATIC ARTHRITIS AND PSORIASIS PATIENTS: A CROSS-SECTIONAL STUDY
   A. Ortolan (Padua, Italy)
OC7:2 DO NOT DO RECOMMENDATIONS IN THE MANAGEMENT OF COMORBIDITY IN PATIENTS WITH AXIAL SPONDYLOARTHITIS. GECOAX PROJECT
   L. Carmona (Madrid, Spain)
OC7:3 EFFECT OF FOOD INTAKE AND AMBIENT PARTICULATE AIR POLLUTION ON ANKYLOSING SPONDYLITIS DISEASE ACTIVITY
   N. Soleimanifar (Tehran, Iran)
OC7:4 BONE DENSITY IN ALGERIAN PATIENTS WITH ANKYLOSING SPONDYLITIS
   B. Bengana (Algiers, Algeria)
OC7:5 EFFICACY AND SAFETY OF USING ETANERCEPT IN TREATMENT OF SPONDYLOARTHRITOPATHIES, EXPERIENCE OF MONTENEGRO
   E. Strujic (Podgorica, Montenegro)
OC7:6 A SUSTAINABLE RELIEF OF CHRONIC LOW BACK PAIN IMMEDIATELY AFTER ONE SESSION OF LOW-LEVEL LASER ACUPUNCTURE THERAPY
   D. Houssien (Jeddah, Saudi Arabia)

Chair – INTRODUCTION:
R. Gerli (Perugia, Italy)

08.30 – 09.40 Libeccio Room

SPECIAL ULTRASOUND SESSION: What about pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases?

Concomitant Session

Speakers:
8.30 Ultrasound in Rheumatology: what, why, when do we assess musculoskeletal tissues and other organs?
   A. Iagnocco (Turin, Italy)
8.50 Tips and tricks for pitfalls and misinterpretations related to the nutritional status in Rheumatic Diseases
C. Martinoli (Genoa, Italy)

9.20 Clinical cases: Ultrasound examinations in patients with nutritional status abnormalities
Chair:
A. Iagnocco (Turin, Italy)

9.40 – 10.50 Platea Maestrale Room

EIGHTH SESSION: Osteoporosis and lifestyle

Speakers:
9.40 Epidemiology, nutritional aspects and environmental factors
L. Carmona (Madrid, Spain)

9.55 The early disease: clinical features and diagnostic tools
L. Sinigaglia (Milan, Italy)

10.10 Management: from guidelines up to the last treatment issues
M.L. Brandi (Florence, Italy)

10.25 Management: non pharmacological aspects and unmet needs
J.A.P. Da Silva (Coimbra, Portugal)

Chairs: M.L. Brandi (Florence, Italy), L. Carmona (Madrid, Spain)

9.40 – 10.50 Levante – Ponente Room

EIGHTH SESSION: Osteoporosis and lifestyle

Concomitant Session and related Oral Communications

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion.

Oral Communications:
OC8:1 CHARACTERIZATION OF A NOVEL VITAMIN D RECEPTOR (VDR) POLYMORPHISM BY SEQUENCE-BASE TYPING
M.C. Padula (Potenza, Italy)

OC8:2 ANKYLOSING SPONDYLITIS BONE: “STIFF AND BRITTLE AS A CRYSTAL GOBLET”
S. Paolino (Genoa, Italy)

OC8:3 VERTEBRAL BONE MINERAL DENSITY EVALUATION USING A QUANTITATIVE ULTRASOUND METHOD (ECHOLIGHT) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
R. Decianu (Bucharest, Romania)

OC8:4 FEMORAL NECK BONE MINERAL DENSITY EVALUATION USING A QUANTITATIVE ULTRASOUND METHOD (ECHOLIGHT) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
R. Decianu (Bucharest, Romania)

OC8:5 COMPARISON OF THE EFFECT OF DENOSUMAB ON BONE MINERAL DENSITY OF LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS, WHEN ADMINISTERED AS FIRST-LINE THERAPY OR AFTER BISPHOSPHONATE
E. Mole (Kifisia, Greece)

OC8:6 CASE REPORT - CALCIUM INTAKE IN RHEUMATIC DISEASES: “EST MODUS IN REBUS”
S. Paolino (Genoa, Italy)

Chair – INTRODUCTION:
R. Ionescu (Bucharest, Romania)
Saturday, April 14th 2018

09.40 – 10.50 Libecchio Room **NO CME ACTIVITY**

**PATIENT SESSION: The cold hand: from symptom to diagnosis**

**SESSIONE DEDICATA AI PAZIENTI: La mano fredda: dal sintomo alla diagnosi**

**Concomitant Session**

**Speakers:**

The cold hand: the symptom

*F. Ingegnoli* (Milan, Italy)

The cold hand: the diagnosis

*V. Smith* (Ghent, Belgium)

**Chairs:**

*V. Smith* (Ghent, Belgium), *F. Ingegnoli* (Milan, Italy)

10.50 – 11.20 Poster and Exhibition Area

**Coffee break**

11.20 – 12.30 Platea Maestrale Room

**NINTH SESSION: Sjögren syndrome today**

**Speakers:**

11.20 New nutritional aspects as possible risk factors: the role of salt

*S. Colafrancesco* (Rome, Italy)

11.35 The early disease: clinical features and diagnostic tools

*A. Tzioufas* (Athens, Greece)

11.50 Management: from guidelines up to the last treatment issues

*X. Mariette* (Paris, France)

12.10 Management: non pharmacological aspects and unmet needs

*L. Quartuccio* (Udine, Italy)

**Chairs:**

*X. Mariette* (Paris, France), *A. Tzioufas* (Athens, Greece)

11.20 – 12.30 Levante – Ponente Room

**NINTH SESSION: Sjögren syndrome today**

**Concomitant Session and related Oral Communications**

Oral Sessions are 70-minute sessions and have 10-minute Chairman’s introduction and 6 oral presentations of 10 minutes each included 2 minutes for discussion

**Oral Communications:**

**OC9:1** ERDJ5 FUNCTION IS INVOLVED IN INFLAMMATORY MANIFESTATIONS OF SJÖGREN'S SYNDROME IN THE SALIVARY GLAND

*A. Tzioufas* (Athens, Greece)

**OC9:2** LOW MIR200B-5P LEVELS IN MINOR SALIVARY GLANDS ASSOCIATE WITH LYMPHOMA DEVELOPMENT IN PATIENTS WITH SJÖGREN'S SYNDROME (SS)

*A. Tzioufas* (Athens, Greece)

**OC9:3** SCORING SYSTEMS IN ULTRASOUND OF SALIVARY GLANDS IN SJÖGREN SYNDROME A VIEW OVER TIME

*V. Iorgoveanu* (Bucharest, Romania)

**OC9:4** ULTRASONOGRAPHIC SCORING OF THE MAJOR SALIVARY GLANDS: IS THERE A RELATIONSHIP WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS OF GLANDS

*Y. Şahinkaya* (Istanbul, Turkey)

**OC9:5** SJÖGREN SYNDROME: EVALUATION OF THE DISEASE ACTIVITY USING THE ESSDAI IN 70 PATIENTS

*J. Dinis De Freitas* (Coimbra, Portugal)
Saturday, April 14th 2018

OC9:6 CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SJOGREN SYNDROME: A RETROSPECTIVE MONOCENTRIC TUNISIAN COHORT

M. Kechida (Monastir, Tunisia)

Chair – INTRODUCTION:
N. Damjanov (Belgrade, Serbia)

11.20 – 12.30 Libeccio Room NO CME ACTIVITY

PATIENT SESSION: Balneotherapy explained
SESSIONE DEDICATA AI PAZIENTI: La balneoterapia spiegata: Come usarla?
Concomitant Session

Speakers:
T. Bender (Budapest, Hungary)
A. Fioravanti (Siena, Italy)

Chairs:
L. Di Matteo (Pescara, Italy), Z. Szekanecz (Debrecen, Hungary)

12.30 – 12:45 Platea Maestrale Room

CLOSING REMARKS

Further variations to the Scientific Program should be expected before the Congress
Friday, April 13th 2018

11.20 – 11.50 Platea Maestrale Room
**Concomitants Industry SATELLITE LECTURE**
*New targets in RA treatment: the case of Janus Kinases inhibition*
**Speaker:**
R. Caporali *(Pavia, Italy)*

11.20 – 11.50 Levante – Ponente Room
**Concomitants Industry SATELLITE LECTURE**
*Gout, a disease of our days: 2018 therapeutical innovations*
**Speaker:**
L. Punzi *(Padua, Italy)*

11.50 – 12.50 Platea Maestrale Room
**Concomitants Industry SATELLITE SYMPOSIUM**
*PAH_CTD: new insights*
**Speakers:**
- PAH in rheumatic diseases
  M. Matucci-Cerinic *(Florence, Italy)*
  ESC/ERS PH Guidelines and treatment strategies
  M. Palazzini *(Bologna, Italy)*
  The GRIPHON Study: CTD subgroup analysis
  C. Denton *(London, UK)*
**Chairs:**
M. Cutolo *(Genoa, Italy)*, V. Smith *(Ghent, Belgium)*

11.50 – 12.20 Levante-Ponente Room
**Concomitants Industry SATELLITE SYMPOSIUM**
*Patient profiling for therapy with Apremilast in psoriaritic arthritis*
**Speaker:**
A. Marchesoni *(Milan, Italy)*

12.20 – 12.50 Levante-Ponente Room
**Concomitants Industry SATELLITE SYMPOSIUM**
*IL6: the key of rheumatoid arthritis*
**Speaker:**
S. Bugatti *(Pavia, Italy)*
Exhibition Booth Grünenthal

**MEET THE EXPERT**

Meet the Expert organizzato con il contributo educazionale di Grünenthal

Lesinurad - The long awaited innovation in Gout

*P. Richette (Paris, France)*

---

**POSTER TOUR**

**Friday, April 13th 2018**

12.50 – 14:00  Poster Area

**Poster Tour 1:** Autoinflammatory and Rare Connective Tissue Diseases

**Poster Tour 2:** Gout and arthritis in dismetabolic conditions

**Poster Tour 3:** Osteoarthritis: Thermal and pharmacological management

**Poster Tour 4:** Osteoporosis/Osteomalacia and malabsorption

**Poster Tour 5:** Psoriatic arthritis / spondyloarthritis

**Poster Tour 6A-B:** Rheumatoid arthritis

**Poster Tour 7:** Sjogren Syndrome and endocrine rheumatic disorders

**Poster Tour 8A-B:** Systemic lupus erythematosus / Antiphospholipid syndrome

**Poster Tour 9A-B:** Systemic Sclerosis and Raynaud phenomenon

---

12.50 – 14:00  Poster Area

**Poster Tour 1:** Autoinflammatory and Rare Connective Tissue Diseases

**Chair:**

*L. Cantarini (Siena, Italy)*

**PT1:001**

**IDIOPATHIC INFLAMMATORY MYOPATHIES: CLINICAL CHARACTERISTICS, SURVIVAL AND POOR PROGNOSTIC FACTORS OF 110 PATIENTS FROM TURKEY**

E. Oguz, M. Erdugan, B. Artim Esen, A. Gul, L. Ocal, M. Inanc (*Istanbul, Turkey*)

**PT1:002**

**PARADOXICAL MONOARTHRITIS IN THE CASE RECEIVING ADAлимМУМAB TREATMENT DUE TO HIDRADENITIS SUPPURATIVE**

S.E. Esmen, S. Arslan, I. Guney (*Konya, Turkey*)

**PT1:003**

**DERMATOMYOSITIS ASSOCIATED WITH PAPILLARY THYROID CANCER: A CASE REPORT AND REVIEW OF LITERATURE**

S. Ugurul, U. Yilmaz, H. Ozdogan (*Istanbul, Turkey*)

**PT1:004**

**SARCOIDOSIS FOLLOWING MYCOPLASMA PNEUMONIAE INFECTION**

I. Sofianos, G. Spiliotis, P. Tzanis, I. Mirokofaliotakis (*Voula, Greece*)

**PT1:005**

**A DIAGNOSTIC AND THERAPEUTIC CHALLENGE - BEHCET’S DISEASE**

A. Savulescu, L. Clioica, A. Dumitru, I. Sirbu, L. Panturu, D. Anghel (*Bucharest, Romania*)

**PT1:006**

**ARTHRITIS – THE SUBSTRATE OF A RARE DERMATOLOGIC DISEASE**

C. Radu, L. Groseanu (*Bucharest, Romania*)

**PT1:007**

**SERUM VISFATIN LEVELS IN BEHCET’S DISEASE PATIENTS**

Z. Ozbalkan-Aslar, M. Eneck, G. Keskin, Y. Araaslan (*Ankara, Turkey*)
LYMPHOMA CASE IMITATING TAKAYASU ARTERITIS
G. Kimyon, R. Erdem, E. Micoogullari, R. Mercan (Hatay, Turkey)

TAKAYASU’S ARTERITIS: EXPERIENCE OF A SINGLE TERTIARY CENTER

A GOOD MIMIC: PMR - IS PMR THE ACCURATE DIAGNOSIS?: A SINGLE- CENTER STUDY

SYSTEMIC SARCOIDOSIS ASSOCIATED WITH VIRAL HEPATITIS C : FORTUITOUS ASSOCIATION OR A CAUSAL EFFECT ?
M. Kechida, R. Mesfar, W.B. Mansour, M. Hafsa, S. Hammami, I. Khochtali (Monastir, Tunisia)

TOCILIZUMAB AS POTENTIAL FIRST OPTION BIOLOGIC THERAPY IN SNITZLER’S SYNDROME
E.S. Daia-Iliescu, C. Buzatu, R. Ionescu (Bucharest, Romania)

THE IMPACT OF PROLONGED CORTICOTHERAPY ON DAMAGE PROGRESSION IN PATIENTS WITH BEHÇET’S DISEASE
E.S. Daia-Iliescu, C. Buzatu, I. Saulescu, A. Borangiu, L. Groseau, V. Bojinca, F. Berghoa, D. Predeteanu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

TERTIARY SYPHILISIS IN A PATIENT WITH TRAPS UNDER CANAKINUMAB TREATMENT: CASE REPORT
D. Temiz Karadag, A. Yazici, A. Cefle (Kocaeli, Turkey)

ADULT STILL’S DISEASE – SERIES OF CLINICAL CASES IN A ROMANIAN REFERENCE CENTER

**Poster Tour 2: Gout and arthritis in dismetabolic conditions**
*Chair: L. Punzi (Padua, Italy)*

MUSCULOSKELETAL ULTRASOUND ABNORMALITIES IN PATIENTS ON DIALYSIS
R. Decianu, M. Bojinca, C. Capusa, A. Zugravu, V.C. Bojinca (Bucharest, Romania)

EFFECT OF LOSARTAN IN LOWERING THE LEVEL OF URIC ACID IN PLASMA IN ALBANIAN PATIENTS WITH HYPERURICEMIA AND HYPERTENSION
M. Jordhani, D. Ruci, V. Duraj (Tirana, Albania)

PULMONARY ADENOCARCINOMA PRESENTED WITH ARTHRITIS
S.E. Esmen, H. Erdogan, E. Kurtipek (Konya, Turkey)

**Poster Tour 3: Osteoarthritis: Thermal and pharmacological management**
*Chair: T. Bender (Budapest, Hungary)*

PATIENT’S EXPERIENCE OF ALTERED BODY PERCEPTION IN MUSCULOSKELETAL AND RHEUMATIC CONDITIONS
A. Viceconti, D. Luzzi, E. Camerone, M. Testa (Savona, Italy)

A LOW FERMENTABLE OLIGO-DI-MONOSACCHARIDES AND POLYOLS DIET IMPROVES SYMPTOMS WITHOUT AFFECTING BODY COMPOSITION AND EXTRACELLULAR BODY WATER IN FIBROMYALGIC PATIENTS WITH IRRITABLE BOWEL SYNDROME
A. Rossi, M. Bellini, A. Ricciardi, S. Marchi, S. Talarico, M. Mosca, L. Bazzichi (Pisa, Italy)

CONTROL AND MANIPULATION OF CONTEXTUAL FACTORS IN MUSCULOSKELETAL PAIN MANAGEMENT. A VALID OPPORTUNITY TO ENHANCE THE EFFECTIVENESS OF THE SPECIFIC THERAPY
G. Rossettini (1), E. Carlino (2), A. Palese (3), M. Testa (1) (1) Genoa (Italy), (2) Turin (Italy), (3) Udine (Italy)
PT3:022 Efficacy and Safety of Intra-Articular Corticosteroid Ultrasound-Guided Injection in Erosive Hand Osteoarthritis

PT3:023 Could Hybrid Hyaluronic Acid Represent a Valid Approach to Treat Rizoarthrosis? A Retrospective Comparative Study
S. Tenti, S. Cheleschi, S. Giannotti, M. Galeazzi, N.A. Giordano, A. Fioravanti (Siena, Italy)

PT3:024 Pain in Knee: More Than Just Wear and Tear Due to Osteoarthritis
M. Parvu, G. Novac, A. Nistor, I. Scheip, S. Voidazan (Tg Mures, Romania)

PT3:025 Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: Two Years Efficacy of a Quarterly Regimen
F. Galluccio, M. Capassoni, M. Matucci Cerinic (Florence, Italy)

PT3:026 The Effectiveness of Saffron Pill in Treatment of Osteoarthritist: A Randomized, Double-Blind Controlled Trial
M. Fiorozzabadi (1), M. Aghei (1), S.Z. Mirfeizi (2), G.R. Roshandel (3), N. AbdolAhi (1)
(1) Golestan (Iran), (2) Razavi Khorasan (Iran), (3) Gorgan (Iran)

PT3:027 Balneotherapy in Knee Osteoarthritis: A Cost/Effectiveness Analysis Alongside an Italian Randomized Controlled Clinical Trial
A. Fioravanti (1), O. Ciani (2), S. Tenti (3), C. Giannitti (1), M. Meregaglia (2), M. Galeazzi (1)
(1) Siena (Italy), (2) Milano (Italy), (3) Siena (Italy)

Poster Tour 4: Osteoporosis/Osteomalacia and malabsorption
Chair: S. Sokolovic (Sarajevo, Bosnia and Herzegovina)

PT4:028 Vitamin D Deficiency in the Acute Care Unit. Is It Related to Survival?
I. Kostoglou-Athanassiou (1), E. Pantazi (1), I. Mavropoulos (1), O. Skioti (1), D. Kousouris (1), S. Kontogiannis (1), P. Athanassiou (2)
(1) Athens (Greece), (2) Thessaloniki (Greece)

PT4:029 Vitamin D Deficiency and Osteomalacia in Acutely Ill Patients After Surgical Treatment for Colon Cancer
P. Athanassiou (1), L. Athanassiou (2), P. Potamousi (2), R. Alevizou (2), M. Digalakis (2), I. Kostoglou-Athanassiou (2)
(1) Thessaloniki (Greece), (2) Athens (Greece)

PT4:030 Effectiveness of Denosumab in Adjustment of Osteoporosis Treatment in Patients with Rheumatoid Arthritis
R. Yatsyshyn, O. Shtefiuk, I. Popadynets, G. Kuryliv, I. Stroika (Ivano-Frankivsk, Ukraine)

PT4:031 Evaluation of Effects of Adapted Physical Activity Program on Functional Organic Indexes and BMD in Osteoporotic Patients Treated with Denosumab
A. Romeo, C. Baiano (Syracuse, Italy)

PT4:032 Breast Cancer and Skeletal Health: Evaluation of Bone Mineral Density and Fracture Risk
S. Paolino, E. Gotelli, V. Tomatis, R. Murialdo, L. Tixi, R. Gonella, A. Ballestero, M. Cutolo (Genoa, Italy)

PT4:033 The 3-Year Efficacy of Zoledronic Acid on Bone Mineral Density of Lumbar Spine and Femoral Neck in Postmenopausal Women with Osteoporosis
E. Moles, K. Zoupidou, A. Alexoudis, D. Moshou, G. Prelorentzos, S. Gazi (Kifissia, Greece)

PT4:034 Tendencies of Bone Mineral Density in Young Adults and the Influence of Diet and Other Lifestyle Habits
I. Badea (Bucharest, Romania)
Poster Tour 5: Psoriatic arthritis / spondyloarthritis

Chair: 
R. Ramonda (Padua, Italy)

PT5:035 THE PREVALENCE AND COMORBIDITIES ASSOCIATED WITH PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS: AN OBSERVATIONAL COHORT STUDY
A. Abdalla (1), M. Abd El Haleem (2) 
(1) Aswan (Egypt), (2) Benha (Egypt)

PT5:036 ASSOCIATION BETWEEN LIVER STEATOSIS, METABOLIC PROFILE AND RHEUMATOLOGIC DISEASES: A SINGLE CENTER STUDY
C. Bruno, R. Grembiale, L. Abenavoli, S. Naty (Catanzaro, Italy)

PT5:037 OBESITY AND RESPONSE TO TNF INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS – DATA FROM A ROMANIAN COHORT
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, C. Iordache, I. Esanu, R. Chirieac (Iasi, Romania)

PT5:038 PREVALENCE OF COMORBIDITIES IN PSORIATIC ARTHRITIS: A CROSS-SECTIONAL STUDY

PT5:039 HYPERURICEMIA IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS
T.E. Gudu, A. Peltea, A. Balanescu, V. Bojinca, D. Opris-Belinski, D. Predeteanu, R. Ionescu (Bucharest, Romania)

PT5:040 METABOLIC SYNDROME AND ANKYLOSING SPONDYLITIS IN ALGERIAN PEOPLE
R. Benaziez-Boutaleb, O. Cheikh, M. Berkache, M. A. Ifticene., C. Dahou-Makhloufi (Algiers, Algeria)

PT5:041 PARADOXICAL INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHROPATHIES TREATED WITH ANTI-TNF AGENTS
C. Ancuta, C. Pomirleanu, R. Paiu, E. Ancuta, R. Chirieac (Iasi, Romania)

PT5:042 ASAS HEALTH INDEX AND ENVIRONMENTAL FACTORS (ASAS HI/EF) IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND CONCOMITANT FIBROMYALGIA
I. Shapoval, M. Stanislavchuk, K. Zaichko (Vinnytsia, Ukraine)

PT5:043 DNA METHYLOME AND SERUM PROTEOME ANALYSES IDENTIFY NEW BIOMARKERS OF PSORIASIS AND PSORIATIC ARTHRITIS IN MONOZYGOTIC TWINS
M. Meroni (1) A. Ceribelli (1), E.M. Paraboschi (1), N. Isailovic (1), E. Generali (1), M. Robusto (1), M. De Santis (1), G. Cardamone (1), F. Sacrini (1), A. Costanzo (1), S. Duga (1), C. Selmi (2) 
(1) Rozzano (Italy), (2) Milan (Italy)

PT5:044 PROTEIN LEVELS AND AUTOANTIBODIES AGAINST LL37 AND IFI16 NUCLEIC ACID SENSORS IN PSORIATIC ARTHRITIS
M. Meroni (1) N. Isailovic (1), M. De Santis (1), A. Ceribelli (1), E. Generali (1), L. Altamore (2), G. Sabatino(2), P. Rovero (2), A.M. Papini (2), V. Caneparo (3), S. Landolfo (3), M. Gariglio (4), M. De Andrea (3), C. Selmi (1,5) 
(1) Rozzano (Italy), (2) Florence (Italy), (3) Turin (Italy), (4) Novara (Italy), (5) Milan (Italy)

PT5:045 THE INFLUENCE OF SMOKING ON RESPONSE TO ANTI TNF THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS
D. Anghel, C. Jurcu, C. Ancuta, M.M Negru, A.E. Savulescu, L. Panturu (Bucharest, Romania)

PT5:046 FACTORS ASSOCIATED WITH STOPPING BIOLOGICAL TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS
G. Iftimie, C. Buta, L. Groseanu, R. Ionescu, D. Opris-Belinski (Bucharest, Romania)

PT5:047 ULTRASONOGRAPHIC CHANGES OF ASYMPTOMATIC ANTERIOR CHEST WALL JOINTS IN ANKYLOSING SPONDYLITIS AND THEIR RELATION TO CHEST EXPANSION
F. Hassan (1), M. Mortada (1), A. Bakry (1), A. Elsammak (1) 
(1) Zagazig (Egypt)

PT5:048 GLOBAL HEALTH ASSESSMENT BY RHEUMATOLOGIST AND BY PATIENT IN PSORIATIC ARTHRITIS, RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS
F. Grubisic, H. Skala Kavanagh, I. Doko, S. Grazio (Zagreg, Croatia)
TWO-YEARS SURVIVAL OF USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS

R.D. González Benítez, I. Janta, B. Serrano Benavente, J. C. Nieto Gonzalez, M. Correyero,
C.M. González Fernandez (Madrid, Spain)

PROMPT CLINICAL RESPONSE TO SECUKINUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: REAL-LIFE OBSERVATIONAL DATA FROM THREE ITALIAN REFERRAL CENTERS

S. Gentileschi (1), A. Vitale (1), D. Rigante (2), G. Lopalco (3), G. Emmi (4), I. Orlando (1), G. Di Scala (4),
J. Sota (1), C. Fabiani (5), B. Frediani (1), M. Galeazzi (1), G. Lapadula (3), F. Iannone (3), L. Cantarini (1)
(1) Siena (Italy) (2) Rome (Italy) (3) Bari (Italy) (4) Florence (Italy) (5) Milan (Italy)

THE ASSESSMENT OF THE RELATION BETWEEN SERUM URIC ACID LEVEL AND DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS

I.H. Dursun, F. Cosan, B. Yilmazer, A. Cefle (Kocaeli, Turkey)

OBESITY INTERACTS WITH RESPONSE AND INCREASES THE RISK OF HYPERTRANSAMINEMINA IN PSORIATIC ARTHRITIS

L. Carmona (1), E. Galíndez (2)
(1) Madrid (Spain) (2) Bilbao (Spain)

Poster Tour 6A: Rheumatoid arthritis

Chair:
A. Alunno (Perugia, Italy)

RITUXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A PATIENT WITH COMORBIDITY – CHONDROSARCOMA/OSTEOSARCOMA OF THE CAVERNOUS SINUS

M.Baresic, L Simetic, D Herceg, B Anic (Zagreb, Croatia)

PERIPHERAL BLOOD B-CELL SUBSETS IN PATIENTS WITH VERY EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS

A. Avdeeva, A. Aleksankin, T. Popkova, E. Suponitskaya, E. Nasonov (Moscow, Russia)

IS IT POSSIBLE TO REPLACE THE RADIOLOGICAL ASSESSMENT OF DESTRUCTIVE CHANGES IN RHEUMATOID ARTHRITIS (RA) BY ULTRASOUND (US) EXAMINATION?

O. Alexeeva, A. Smirnov, A. Volkov, E. Nasonov (Moscow, Russia)

EDUCATING PEOPLE WITH RMDS TO FOLLOW A CORRECT DIET: AN INNOVATIVE 3 STEPS PROJECT

U.G. Viora, S. Severoni, S. Tonolo (Rome, Italy)

FOLIC ACID SUPPLEMENTATION REDUCES METHOTREXATE EFFICACY AND DELAY CLINICAL IMPROVEMENT IN RHEUMATOID ARTHRITIS PATIENTS

A. Sulli, S. Paolino, C. Pizzorni, E. Alessandri, M. Patane’, M. Ghio, M. Cutolo (Genoa, Italy)

CLINICAL AND ECONOMIC VALUE OF SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS IN THE MEDITERRANEAN AREA

B. Mascialino (1), S. Swiniarski (2), I. Gehring (2), M. Poorafshar (1)
(1) Uppsala (Sweden), (2) Freiburg (Germany)

CAN DIET MODIFY RISK AND COURSE OF INFLAMMATION AND MALIGNANCY?

E. Kucharz (Katowice, Poland)

TRADITIONAL TYPE 2 DIABETES RISK FACTORS AND INSULIN RESISTANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

L. Kondrateva, T. Popkova (Moscow, Russia)

THE EFFECT OF TOCILIZUMAB THERAPY ON THE BODY MASS INDEX, WAIST AND HIP CIRCUMFERENCE, LIPIDS PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS

E. Gerasimova, T. Popkova, A. Martinova, E. Zhilyaev, G. Lukina (Moscow, Russia)

SMOKING AND RHEUMATOID ARTHRITIS

D. Dusa, M. Suta (Constanta, Romania)

A PATIENT PRESENTING WITH JAW PAIN. DIAGNOSIS, TREATMENT AND REVIEW OF THE LITERATURE

C. Christodoulou (Larnaca – Nicosia, Cyprus)
THE INFLUENCE OF ABATACEPT ON BIOMARKERS LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS

THE INFLUENCE OF SMOKING ON CLINICAL RESPONSE TO ETANERCEPT THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Zivojinovic, M. Bukilica, N. Damjanov (Belgrade, Serbia)

SECONDARY SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS
R. Yatsyshyn, I. Stoika (Ivano-Frankivsk, Ukraine)

DIET IN CHILDREN WITH IJA: AN INNOVATIVE 4 STEPS PROJECT TO OVERCOME CULTURAL BARRIERS
U.G. Viora, G. Mascarino, S. Tonolo (Rome, Italy)

27-YEARS OLD FEMALE WITH POLYARTHRITIS, DRYNESS SYNDROME AND ACUTE LOSS OF VISUAL ACUITY
P. Tzanis, I. Sofianos, G. Spiliotis, I. Myriokefalitakis (Voula, Greece)

Poster Tour 6B: Rheumatoid arthritis
Chair: M. Cimmino (Genoa, Italy)

RHEUMATOID ARTHRITIS PATIENT WITH MASS ON THE ANTERIOR CHEST WALL
O. Soysal Gunduz, G. Gunduz, D. Demir (Manisa, Turkey)

A STRUCTURED PROTOCOL FOR THE EVALUATION OF CARDIO-VASCULAR RISK IN ARTHRITIS PATIENTS
F. Sivera, N. Alberola, G. Albert, C. Fernandez-Carballedo, R. Martin, T. Pedraz (Elda, Spain)

EFFECTS OF MEDITERRANEAN DIET AND PHYSICAL THERAPY IN EARLY STAGES OF Oligoarticular Juvenile Idiopathic Arthritis
L.M. Ailioaie, C. Ailioaie (Iasi, Romania)

CONSTRUCT VALIDITY, REPRODUCIBILITY AND FEASIBILITY OF THE PRO-TERMOMETER-5ITEM (5T-PROS) IN THE EVALUATION OF THE HEALTH STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS AND FIBROMYALGIA
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)

CONSTRUCT VALIDITY AND INTERPRETABILITY OF THE QUICKDASH IN THE ASSESSMENT OF RHEUMATOID ARTHRITIS HAND DISABILITY
F. Salaffi, S. Farah, M. Di Carlo, M. Carotti (Ancona, Italy)

EVOLUTION OF PAIN IN RHEUMATOID ARTHRITIS TREATED WITH ANTI-INTERLEUKIN 6
N. Blidi, N. Saidi, R. Benaziez, N. Zehraoui, M.A. Ilicenc, F. Mechid, C. Dahou-Makhlioufi (Algiers, Algeria)

PATIENTS' SATISFACTION WITH HEALTH CARE PROVIDED IN AN OUTPATIENT CLINIC FOR RHEUMATOLOGY: RESULTS OF A QUESTIONNAIRE STUDY OF SPECIFIC ASPECTS OF CARE
D. Cubelic (1), M. Reihl (2), M. Mayer (1), B. Anic (1)
(1) Zagreb (Croatia), (2) Vukovar (Croatia)

PREDICTIVE FACTORS OF EVOLUTION OF EARLY INFLAMMATORY ARTHRITIS TO RHEUMATOID ARTHRITIS
F. Rahal, R. Chetouane, S. Haid, N. Brahimi, A. Ladjouze-Rezig, F. Hanni (Algiers, Algeria)

ULTRASONOGRAPHY FINDINGS OF HIP JOINTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Prodanovic, G. Radunovic, N. Damjanov (Belgrade, Serbia)

RITUXIMAB: COMPARISON CLINICAL AND ANTI-DESTRUCTIVE EFFECTS AND B-CELL COUNT IN RHEUMATOID ARTHRITIS PATIENTS.
A. Pivanova, G. Lukina, Y. Sigidin, A. Smirnov, S. Glukhova, A. Kuznetsova, K. Kuzikyants, E. Nasonov (Moscow, Russia)
PT6B:081 EFFECT OF A DYNAMIC EXERCISE PROGRAM IN COMBINATION WITH A MEDITERRANEAN DIET IN WEIGHT AND HANDGRIP STRENGTH IN WOMEN WITH RHEUMATOID ARTHRITIS

PT6B:082 RHEUMATOID ARTHRITIS: FREQUENCY AND INFLUENCE OF TOBACCO AND BODY MASS INDEX (BMI) IN THE ACTIVITY OF THE DISEASE
E. Mussano, L. Onetti, I. Cadile, M. Werner, M.V. Gazzoni, M.C. Taboada, M.I. Stancich, R. Jurado (Cordoba, Argentina)

PT6B:083 PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS: CASE-CONTROL STUDY
F. Mechid, C. Dahou, M. Meddad, S. Salah, S. Merad (Algiers, Algeria)

PT6B:084 CONTRIBUTION OF VITAMIN D RECEPTOR FOKI GENE POLYMORPHISM ON DISEASE SEVERITY AND LONG TERM DISEASE OUTCOME IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
D. Lazarević (1), J. Vojinović (1), G. Susic (2), J. Basic (1), J. Milenković (1)
(1) Niš (Serbia), (2) Belgrade (Serbia)

PT6B:085 IS PROTEIN C REACTIVE RELATED TO METABOLIC SYNDROME IN RHUMATOID ARTHRITIS?
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Klii (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liège (Belgium)

PT6B:086 THE EFFICACY AND SAFETY OF METHOTREXATE IN A DOSE 25 MG PER WEEK AND MORE IN PATIENTS WITH RHUMATOID ARTHRITIS.
G. Gridneva, Y. Muraviev (Moscow, Russia)

Poster Tour 6C: Rheumatoid arthritis
Chair: A. Iagnocco (Turin, Italy)

PT6C:087 IMPAIRED WOUND HEALING DUE TO LEFLUNOMIDE USE IN PATIENTS WITH RHEUMATOID ARTHRITIS
V. Gerdan (Izmir, Turkey)

PT6C:088 THE EFFECT OF GENDER ON ANEMIA FREQUENCY IN RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

PT6C:089 THE RELATIONSHIP OF ANEMIA FREQUENCY AND DISEASE ACTIVITY IN THE PATIENTS WITH RHEUMATOID ARTHRITIS
S.E. Esmen, A. Tekinalp (Konya, Turkey)

PT6C:090 KIR GENE DISTRIBUTION IN TURKISH PATIENTS WITH RHEUMATOID ARTHRITIS
E. Erken, F. Kocabas, O. Ozturk, S. Dinkci, N. Yilmaz (Adana, Turkey)

PT6C:091 FACTORS CONTRIBUTING TO DISABILITY IN RHEUMATOID ARTHRITIS PATIENTS: AN EGYPTIAN MULTICENTER STUDY
M. Eissa (1), M. Hammad (2), G. Dawa (2)
(1) Cairo (Egypt), (2) Zaqazig (Egypt)

PT6C:092 NEW DYNAMOMETRIC PARAMETERS IN EVALUATION OF HAND FUNCTION IN RHEUMATOID ARTHRITIS BASED ON DYNAMIC MEASUREMENTS– A PILOT EVALUATION STUDY
I. Doko, A. Dubravic, I. Michielni, B. Medved Rogina, S. Grazio (Zagreb, Croatia)

PT6C:093 PYODERMA GANGRENOSUM: A PARADOXICAL SIDE EFFECT IN A RHEUMATOID ARTHRITIS PATIENT TREATED WITH GOLIMUMAB
T. Dimitroulas, D.M. Manoll, A. Skalikou, V. Douros, K. Petidis, S. Vakiris, A. Pyrasopoulos (Thessaloniki, Greece)

PT6C:094 METHOTREXATE INTOXICATION: BEYOND THE ADVERSE EVENTS
E. Dalkilic, B.N. Coskun, B. Yagiz, S. Ermurat, A.N. Tufan, Y. Pehlivan (Bursa, Turkey)

PT6C:095 ORAL STATUS IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS OF AN ALGERIAN STUDY
C. Dahou-Makhloufi, F. Mechid, R. Benaziez, M. Meddad, S.S. Salah, N. Zehraoui, S. Merad (Algiers, Algeria)
LOW RHEUMATOID ARTHRITIS PREVALENCE IN ALGERIA: A MEDITERRANEAN SINGULARITY?

IMMUNOCORRECTIVE THERAPY IN THE COMPLEX TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, H. Krustaleva, H. Kolupaeva (Minsk, Belarus)

CLINICAL AND ULTRASOUND CONCORDANCE IN RHEUMATOID ARTHRITIS
R. Chetouane (Algiers, Algeria)

A PRACTICAL CONSENSUAL APPROACH TO MANAGE COMORBIDITY IN RHEUMATOID ARTHRITIS
L. Carmona, S. Castañeda (Madrid, Spain)

SAFETY AND EFFICACY OF A TRIVALENT, INACTIVATED INFLUENZA VACCINE IN PATIENTS WITH RHEUMATIC DISEASES (PRELIMINARY RESULTS)
D. Bukhanova, B. Belov, G. Tarasova, M. Cherkasova, S. Erdesz, T. Dubinina, N. Demidova, A. Volkov (Moscow, Russia)

ACUTE LIVER FAILURE AS REACTION TO TOCILIZUMAB THERAPY
M. Bogojevic, N. Miketic, E. Strujic (Podgorica, Montenegro)

FACTORS ASSOCIATED WITH INTOLERANCE OF METHOTREXATE IN PATIENTS WITH INFLAMMATORY JOINT DISEASE
B. Bengana, A. Boukabous, N. Bahaz, S. Mostefai, S. Lefkir-Tafiani (Algiers, Algeria)

SCREENING FOR SKIN MALIGNANCIES AMONG PATIENTS TREATED WITH BIOLOGICS – PILOT STUDY FROM A SINGLE CROATIAN RHEUMATOLOGY CENTER
M. Baresic, R. Jurakic Toncic, B. Marinovic, B. Anic (Zagreb, Croatia)

Poster Tour 7: Sjogren Syndrome and endocrine rheumatic disorders
Chair:
G.D. Kitas (Paris, France)

IS SALIVARY GLAND INHOMOGENEITY AN EARLY ULTRASONOGRAPHIC SIGN IN SJOGREN SYNDROME?
V. Iorgoveanu, D. Mazilu, V. Bojinca, L. Groseanu, D. Belinski, A. Balanescu, C. Constantinescu, V. Vlad, I. Saulescu, M. Gheorghe, D. Predeteanu, R. Ionescu (Bucharest, Romania)

RENAL INVOLVEMENT IN PRIMARY SJOGREN SYNDROME - A CASE REPORT
L. Brites, J. Freitas, M. Luis, J. Rovisco, M. Santiago, C. Duarte, A. Malcata, F. Costa (Coimbra, Portugal)

ANCA-ASSOCIATED VASCULITIS IN A PATIENT WITH PRIMARY SJOGREN SYNDROME
P. Athanassiou, D. Pantelidis, C. Gerodimos (Thessaloniki, Greece)

SECONDARY SJOGREN SYNDROME: CLINICAL FEATURES AND PREDICTIVE FACTORS
M. Kechida (1), N. Lorenzo Vilalba (2), A. Alaya (1), R. Mesfar (1), R. Kili (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liege (Belgium)

VITAMIN D STATUS IN A LUCANIAN COHORT OF ANTI-DFS70/LEDGF POSITIVE ADULT SUBJECTS
T. Carbone, G. Tramontano, M. Gilio, M.C. Padula, A. Padula, V. Pafundi, S. D’angelo (Potenza, Italy)

SYSTEMIC SCLEROSIS IN ELDERLY: A RETROSPECTIVE BI-CENTRIC COHORT
M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Kili (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Liege (Belgium)
Poster Tour 8A: Systemic lupus erythematosus / Antiphospholipid syndrome

Chair: A. Doria (Padua, Italy)

PT8A:110 INFECTION COMORBIDITIES IN SLE PATIENTS - CLINICAL CASES IN A ROMANIAN REFERENCE CENTER

PT8A:111 GANGRENE IN SYSTEMIC LUPUS ERYTHEMATOSUS: ABOUT TWO CASES
N. Blidi, N. Zehraoui, R. Atamane, C. Dahou (Algiers, Algeria)

PT8A:112 VITAMIN D DEFICIENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATIONSHIP WITH DISEASE ACTIVITY
L. Athanassiou (1), I. Kostoglou-Athanassiou (1), C. Katsavouni (2), A. Tzanavari (2), A. Koteli (2), C. Mavragni (1), M. Koutsilieris (1), P. Athanassiou (2) (1) Athens (Greece), (2) Thessaloniki (Greece)

PT8A:113 NAILFOLD CAPILLAROSCOPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL
M. Cutolo (1), K. Melsens (2), S. Wijnant (2), F. Ingemoli (3), K. Thevissen (2), F. De Keyser (2), S. Decuman (2), U. Müller-Ladner (4), Y. Piette (2), V. Ricciieri (5), N. Ughi (3), E. Vandecastelee (2), A. Vanhaecke (2), V. Smith (2) (1) Genoa (Italy), (2) Ghent (Belgium), (3) Milan (Italy), (4) Bad-Nauheim (Germany), (5) Rome (Italy)

PT8A:114 EVALUATION OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY RAYNAUD’S PHENOMENON PATIENTS.
B. Ruaro (1), A. Sulli (1), C. Pizzorni (1), S. Paolino (1), V. Smith (2), M. Pendolino (1), M. Cutolo (1) (1) Genoa (Italy), (2) Ghent (Belgium)

PT8A:115 EXPRESSION OF TNF-A AND IL-6 IN PATIENTS WITH UNTREATED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RELATIONSHIP WITH DISEASE ACTIVITY
T. Panafidina, T. Popkova, E. Alexandrova (Moscow, Russia)

PT8A:116 INCREASED CARDIOVASCULAR AND METABOLIC COMORBIDITIES IN ROMANIAN LUPUS PATIENTS
D. Opris-Belinski, A. Balalanescu, C. Branescu, D. Predeteanu, V. Bojinca, I. Saulescu, L. Groseanu, C. Nicolae, C. Constantinescu, R. Ionescu (Bucharest, Romania)

PT8A:117 CLINICAL MANIFESTATIONS AND LABORATORY MARKERS THAT IMPACT LONG TERM DAMAGE IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

PT8A:118 THE IMPACT OF THE PLACE OF RESIDENCE ON SYSTEMIC LUPUS ERYTHEMATOSUS
I. Gergianaki, C. Adamichou, G. Spyroy, D. Boumpas (1,3), P. Sidirooulos (1), G. Bertis (1) (1) Irakleio (Greece), (2) Athens (Greece), (3) Nikosia (Cyprus)

PT8A:119 OUTCOME OF CHILDHOOD LUPUS NEPHRITIS IN SAUDI CHILDREN
S. Al-Mayouf, A. Alameer, A. Alfattani, A. Alsonbul (Riyadh, Saudi Arabia)

PT8A:120 PHARMACEUTICAL DISRUPTION OF B2GPI CXCL4 COMPLEX USING COMPUTATIONALLY DESIGNED OLIGOPEPTIDES
M. Patsouras, E. Papaconstantinou, E. Eliopoulos, P. Vlachoyiannopoulos (Athens, Greece)

PT8A:121 WHOLE TRANSCRIPTOME ANALYSIS OF APL TREATED HUVECS MAPS PROINFLAMMATORY AND PROCOAGULANT PATHWAYS
M. Patsouras, P. Karagianni, S. Foutas, E. Alexopoulou, M. Aggelopoulos, D. Thanos, A. Tzioufas, P. Vlachoyiannopoulos (Athens, Greece)
Poster Tour 8B: Systemic lupus erythematosus / Antiphospholipid syndrome

**Chair:**

**A. Tincani** *(Brescia, Italy)*

**PT8B:122** IMPACT OF SEVERE ORGANIC CNS INVOLVEMENT IN COGNITIVE FUNCTION IN A COHORT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS, WITH THE ACR-SLE BATTERY

C. Golemati, E. Kampylafka, C. Papageorgiou, P. Vlachoyiannopoulos, **A Tzioufas** *(Athens, Greece)*

**PT8B:123** ANTI-PHOSPHOLIPID ANTIBODIES ARE INDEPENDENTLY ASSOCIATED WITH ATHEROSCLEROSIS IN THE GENERAL POPULATION

M. Meroni (1), C. Selmi (1,2), E. Generali, M. De Santis, P.M. Battezzati, A. Ceribelli, M. Zuin (2)
(1) Rozzano (Italy), (2) Milan (Italy)

**PT8B:124** SHOULD WE SCREEN FOR ATHEROSCLEROSIS AT AN EARLIER AGE FOR WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS?


**PT8B:125** LUPUS NEPHRITIS: SERIES OF 12 CLINICAL CASES IN A ROMANIAN REFERENCE CENTER


**PT8B:126** FEATURES ASSOCIATED WITH OUT-OF-HOSPITAL DEATH IN A GROUP OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DECEASED OVER A 10-YEAR PERIOD

I. Padjen, M. Erceg, M. Cerovec, M. Mayer, R. Stevanovic, **B. Anic** *(Zagreb, Croatia)*

**PT8B:127** FEMALE LUPUS PATIENT OPTIONS REGARDING TREATMENT AND NEGATIVE PREGNANCY OUTCOME

D. Opris-Belinski (1), C. Ancuta (2), M. Pirvu (3), A. Balanescu (1), V. Bojinca (1), I. Saulescu (1), D. Mazilu (1), R. Ionescu (1)
(1) Bucharest (Romania), (2) Iasi (Romania), (3) Tg Mures (Romania)

**PT8B:128** AUTOANTIBODIES AS BIOMARKERS IN THE PREDICTION OF CLINICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS

A.N. Nistor, I. Scheip, M. Parvu, **(Tg Mures, Romania)**

**PT8B:129** LUPUS NEPHRITIS: CLINICAL MANIFESTATIONS AND RISK FACTORS

M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Klii (1), S. Hammami (1), I. Khochtali (1)
(1) Monastir (Tunisia), (2) Belgium (Belgium)

**PT8B:130** TWO CASES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN PATIENTS WITH SLE

Z. Kardum, V. Prus, J. Milas Ahic **(Osijek, Croatia)**

**PT8B:132** PITYRIASIS LICHENOIDES ET VARIOLIFORMIS ACUTA (PLEVA) DEVELOPING DEPENDING ON THE USE OF HYDROXYCHLOROQUINE

S.E. Esmen, S. Arslan **(Konya, Turkey)**

**PT8B:133** LUPUS PREGNANCY: ACHIEVEMENTS AND OPEN ISSUES IN THE MULTIDISCIPLINARY MANAGEMENT

F. Crisafulli (1), L. Andreoli (1), L. Antolini (1), G. Parma (1), C. Benigno (2), A. Lojacono (1), S. Zatti (1), V. Cappa (1), S. Catza (1), A. Tincani (1)
(1) Brescia (Italy), (2) Napoli (Italy)

Poster Tour 9A: Systemic Sclerosis and Raynaud phenomenon

**Chair:**

**V. Smith** *(Ghent, Belgium)*

**PT9A:134** MACROVASCULAR IMPAIRMENT AND LIPID PROFILE IN SYSTEMIC SCLEROSIS PATIENTS

S. Papulino, E. Gotelli, V. Tomatis, B. Colombo, E. Alessandri, M. Ghio, C. Pizzorni, F. Goegan, M. Cutolo **(Genoa, Italy)**

**PT9A:135** PREDICTORS OF MORBIDITY AND MORTALITY IN PATIENTS WITH EARLY SYSTEMIC SCLEROSIS: LONG-TERM FOLLOW-UP FROM A SINGLE CENTRE INCEPTION COHORT STUDY

S. Panopoulos, V.K. Bournia, G. Konstantonis, K. Fragiadaki, P.P. Sfikakis, **M Tektonidoy** *(Athens, Greece)*

---

**Poster Tour 8B:**

1. **PT8B:122** Impact of severe organic CNS involvement in cognitive function in a cohort of systemic lupus erythematosus patients, with the ACR-SLE battery.
   - C. Golemati, E. Kampylafka, C. Papageorgiou, P. Vlachoyiannopoulos, A Tzioufas (Athens, Greece)

2. **PT8B:123** Anti-phospholipid antibodies are independently associated with atherosclerosis in the general population.
   - M. Meroni (1), C. Selmi (1,2), E. Generali, M. De Santis, P.M. Battezzati, A. Ceribelli, M. Zuin (2)
     (1) Rozzano (Italy), (2) Milan (Italy)

3. **PT8B:124** Should we screen for atherosclerosis at an earlier age for women with systemic lupus erythematosus?
   - I. Saulescu, A. Borangiu, D. Opris-Belinski, S. Daia-Ilieanu, L. Groseau, R. Ionescu (Bucharest, Romania)

4. **PT8B:125** Lupus nephritis: series of 12 clinical cases in a Romanian reference center.

5. **PT8B:126** Features associated with out-of-hospital death in a group of patients with systemic lupus erythematosus deceased over a 10-year period.
   - I. Padjen, M. Erceg, M. Cerovec, M. Mayer, R. Stevanovic, B. Anic (Zagreb, Croatia)

6. **PT8B:127** Female lupus patient options regarding treatment and negative pregnancy outcome.
   - D. Opris-Belinski (1), C. Ancuta (2), M. Pirvu (3), A. Balanescu (1), V. Bojinca (1), I. Saulescu (1), D. Mazilu (1), R. Ionescu (1)
     (1) Bucharest (Romania), (2) Iasi (Romania), (3) Tg Mures (Romania)

7. **PT8B:128** Autoantibodies as biomarkers in the prediction of clinical manifestations in systemic lupus erythematosus.
   - A.N. Nistor, I. Scheip, M. Parvu, (Tg Mures, Romania)

8. **PT8B:129** Lupus nephritis: clinical manifestations and risk factors.
   - M. Kechida (1), N. Lorenzo Vilalba (2), R. Mesfar (1), Y. Alvarado Funes (2), R. Klii (1), S. Hammami (1), I. Khochtali (1)
     (1) Monastir (Tunisia), (2) Belgium (Belgium)

9. **PT8B:130** Two cases of thrombotic thrombocytopenic purpura in patients with SLE.
   - Z. Kardum, V. Prus, J. Milas Ahic (Osijek, Croatia)

10. **PT8B:132** Pityriasis lichenoides et varioliformis acuta (PLEVA) developing depending on the use of hydroxychloroquine.
    - S.E. Esmen, S. Arslan (Konya, Turkey)

11. **PT8B:133** Lupus pregnancy: achievements and open issues in the multidisciplinary management.
    - F. Crisafulli (1), L. Andreoli (1), L. Antolini (1), G. Parma (1), C. Benigno (2), A. Lojacono (1), S. Zatti (1), V. Cappa (1), S. Catza (1), A. Tincani (1)
      (1) Brescia (Italy), (2) Napoli (Italy)

---

**Poster Tour 9A:**

12. **PT9A:134** Macrovascular impairment and lipid profile in systemic sclerosis patients.
    - S. Papulino, E. Gotelli, V. Tomatis, B. Colombo, E. Alessandri, M. Ghio, C. Pizzorni, F. Goegan, M. Cutolo (Genoa, Italy)

    - S. Panopoulos, V.K. Bournia, G. Konstantonis, K. Fragiadaki, P.P. Sfikakis, M Tektonidoy (Athens, Greece)
VITAMIN D DEFICIENCY AND GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS. REAL LIFE DATA FROM A REFERRAL CENTER IN NORTHERN GREECE
I. Kostoglou-Athanassiou (1), L. Athanassiou (1), T. Banti (2), M. Gatsiou (2), C. Katsavouni (2), P. Athanassiou (2)
(1) Athens (Greece), (2) Thessaloniki (Greece)

OSTEOPROTEGERIN RELATES WITH BIOMARKER THAT HAVE ROLES IN OSTEOPOROSIS, FIBROSIS, AND VASCULOPATHY IN SYSTEMIC SCLEROSIS: A POTENTIAL MULTIFACETED RELATIONSHIP BETWEEN OPG/RANKL/TRAIL AND WNT INHIBITOR
A. Taylan, M. Birlik, G. Kenar, B. Toptrak, A.R. Sisman (Izmir, Turkey)

PERIPHERAL BLOOD PERFUSION AND HAND DERMAL THICKNESS IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro (1), A. Sulli (1), C. Pizzorni (1), S. Paolino (1), E. Alessandri (1), V. Smith (2), E. Gotelli (1), M. Patanè (1), M. Cutolo (1)
(1) Genoa (Italy), (2) Ghent (Belgium)

EVALUATION OF PERIPHERAL BLOOD PERFUSION IN PRIMARY RAYNAUD'S PHENOMENON AND IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro (1), A. Sulli (1), V. Smith (2), S. Paolino (1), C. Pizzorni (1), A. Trombetta (1), M. Cutolo (1)
(1) Genoa (Italy), (2) Ghent (Belgium)

A SIX MONTH FOLLOW-UP STUDY IN RAYNAUD'S PHENOMENON PATIENTS TREATED WITH AMINAPHTONE
B. Ruaro, S. Paolino, C. Pizzorni, M. Cutolo, A. Sulli (Genoa, Italy)

USE OF BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS (BIVA) FOR THE ASSESSMENT OF BODY COMPOSITION IN A COHORT OF ITALIAN PATIENTS WITH SYSTEMIC SCLEROSIS
A. Rossi, A. Della Rossa, A. D'ascanio, S. Barsotti, S. Bilia, M. Mosca (Pisa, Italy)

NUTRITIONAL STATUS IN SYSTEMIC SCLEROSIS - A POSSIBLE ADDITIONAL TOOL IN ASSESSING DISEASE SEVERITY AND PROGNOSIS
M. Radic, D. Peric, D. Perkovic, D. Marasovic Krstulovic, K. Boric, D. Martinovic Kaliterna (Split, Croatia)

QUANTITATIVE COMPUTED TOMOGRAPHY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: FACE AND CONTENT VALIDITY OF AN OPERATOR INDEPENDENT ALGORITHM BASED ON A FREE OPEN SOURCE SOFTWARE
A. Ariani, M. Silva (Parma, Italy)

IS IT POSSIBLE TO DISCRIMINATE A CLINICAL SUBTYPE OF SYSTEMIC SCLEROSIS ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION?
N. Yudkina, A. Volkov, T. Martynyuk, E. Nikolaeva (Moscow, Russia)

LUNG INVOLVEMENT PARAMETERS AND CLINICAL CORRELATIONS IN SYSTEMIC SCLEROSIS PATIENTS: A SINGLE CENTRE STUDY
A.C. Trombetta (1), E. Alessandri (1), S. Paolino (1), C. Pizzorni (1), M. Ghio (1), B. Ruaro (1), M. Patanè (1), E. Gotelli (1), F. Goegan (1), A. Sulli (1), V. Smith (2), M. Cutolo (1)
(1) Genoa (Italy), (2) Ghent (Belgium)

SERUM KLOTHO CONCENTRATION IS INVERSELY ASSOCIATED TO THE SEVERITY OF NAILFOLD CAPILLAROSCOPIC PATTERN IN SYSTEMIC SCLEROSIS PATIENTS
R. Talotta (1), F. Rigamonti (1), T. Letizia (1), S. Bongiovanni (1), F. Atzeni (2), T. Vago (1), P. Sarzi-Puttini (1)
(1) Milan (Italy), (2) Messina (Italy)

A LARGE-SCALE PROTEOMIC APPROACH IDENTIFIED NEW SERUM BIOMARKERS ASSOCIATED WITH SYSTEMIC SCLEROSIS
M. Meroni (1), M. De Santis (1), E. Generali (1), A. Ceribelli (1), N. Isailovic (1), M. Caprioli (1), G.M. Guidelli (1), C Selm (1,2)
(1) Rozzano (Italy) (2) Milan (Italy)
HOW MUCH TEMPERATURE CAN TRULY IMPACT ON RAYNAUD’S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS?
T. Schioppo, A. Orenti, P. Boracchi, O. De Lucia, A. Murgo, F. Ingegnoli (Milan, Italy)

HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH TWO DIFFERENT INTRAVENOUS ILOPROST REGIMENS
T. Schioppo (1), L. Scalone (1,2), P. Cozzolino (2), L. Mantovani (1,2), G. Cesana (2), O. De Lucia (1), A. Murgo (1), F. Ingegnoli (1)
(1) Milan (Italy) (2) Monza (Italy)

THE D-PRO QUESTIONNAIRE: ASSESSMENT OF THE VITAMIN D STATUS IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolino, V. Tomatis, E. Gotelli, E. Alessandri, M. Patanè, A. Sulli, M. Cutolo (Genoa, Italy)

THE D-PRO QUESTIONNAIRE: ASSESSMENT OF THE VITAMIN D STATUS IN SYSTEMIC SCLEROSIS PATIENTS
S. Paolino, V. Tomatis, E. Gotelli, E. Alessandri, M. Patanè, A. Sulli, M. Cutolo (Genoa, Italy)

NAILFOLD CAPILLAROSCOPY ASPECTS IN UNDIFFERENTIATED CONNECTIVITIES TISSUE DISEASE RESULTS OF A PRELIMINARY STUDY
B. Neftia, S. Dahou, N. Blihi, F. Mechid, C. Dahou-Makhloufi (Algiers, Algeria)

DETERMINANTS OF QUALITY OF LIFE IN SYSTEMIC SCLEROSIS AND PATIENT PERCEPTION OF THE DISEASE

FERTILITY AND PREGNANCY IN SYSTEMIC SCLEROSIS – A EUSTAR CENTER EXPERIENCE

SCLERONET® A MULTICENTER PILOT PROJECT HEADED BY GILS – GRUPPO ITALIANO LOMA SCLERODERMIA
B. Garbagnati, I. Galetti (Milan, Italy)

FUNCTIONAL STATE OF GASTROINTESTINAL TRACT IN CHILDREN WITH SYSTEMIC SCLEROSIS AND LIMITED SCLERODERMA
I. Chyzheuskaya, L. Belyaeva, H. Khrustaleva, H. Kolupaeva, T. Matsushko (Minsk, Belarus)

MODERN APPROACHES TO REHABILITATION OF CHILDREN WITH JUVENILE SKLEROERMA
I. Chyzheuskaya, L. Belyaeva, L. Zajtseva, H. Khrustaleva, H. Kolupaeva, A. Kolomiets (Minsk, Belarus)

ILOPROST INDUCED WEIGHT LOST AND MALNUTRITION IN SYSTEMIC SCLEROSIS PATIENT: A CASE REPORT
C. Bruno, S. Naty, L. Abenavoli, R. Grembiale (Catanzaro, Italy)

FACS CHARACTERIZATION OF CIRCULATING FIBROCYTES FROM LIMITED CUTANEOUS SCLERODERMA PATIENTS
R. Brizzolara, P. Montagna, S. Soldano, A.C. Trombetta, P. Contini, B. Ruaor, S. Paolino, M. Cutolo (Genoa, Italy)

SYSTEMIC SCLEROSIS SINE SCLERODERMA
P. Athanassious, C. Katsavouni, C. Gerodimos (Thessaloniki, Greece)
ABSTRACT BOOK
All the abstracts submitted and accepted will be published in an issue of the Clinical and Experimental Rheumatology Journal, you will be able to collect it at the registration desk. The Abstract Book contains all the Abstracts included all the Lectures and the Scientific Sessions speeches.

Important notice for Authors: further to the Italian regulations for CME accreditation, please be aware that the Abstracts accepted as Oral communications appear on the Final Scientific Program exclusively with the name of the Presenting Author. However, all the abstracts submitted in an issue of the Clinical and Experimental Rheumatology Journal will be fully published with the names of all the authors.

With regard to the accepted Posters they will fully appear with the names of all the Authors on both Final Scientific Program and the issue of the Clinical and Experimental Rheumatology Journal.

ORAL COMMUNICATIONS AND POSTER TOURS

ORAL COMMUNICATIONS
Oral presentations are limited to 8 minutes followed by 2 minutes of discussion. Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 1 hour before the start of their session.

POSTER EXHIBITION AND POSTER TOURS

POSTER EXHIBITION: from Thursday, April 12th to Saturday, April 14th

>Thursday, April 12th from 16.40 to 17.10
Start the Poster Exhibition in the Poster Area

POSTER TOUR:
>Friday, April 13th from 12.50 to 14.00

During the lunch break, all presenting authors should stand by their poster board from 12.50 to 14.00 to speak with fellow delegates and poster Chairmen. Nine parallel Poster Tours have been scheduled related to the 9 Topics of Congress.

GUIDELINES FOR CHAIRPERSONS AND SPEAKERS

Guidelines for chairpersons
• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session
• Respect the timing allowed to the session and to each presentation
• All presentations, discussions and questions must be in English
• English –Italian / Italian-English simultaneous translation will be provided only for the PATIENT SESSIONS
Guidelines for speakers

• Follow the instructions indicated in the paragraph “Audiovisual Instructions”
• Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet the chairpersons
• Respect the timing allowed for your presentation
• All presentations, discussions and questions must be in English
• English – Italian / Italian-English simultaneous translation will be provided only for the PATIENT SESSIONS

Audiovisual instructions

In order to optimise the quality of speaker presentations and to avoid possible problems, all speakers are kindly requested to report to the Slide Centre ample time prior to their talk for preview and uploading of their presentation.

The optimal format for video projection of presentations is Power Point. Other formats are not foreseen.

All meeting rooms include a standard pc workstation at the lectern connected via cable to the Speakers’ Ready Room. The presentations uploaded on the Speakers’ Ready Room pcs are automatically transmitted to the correct meeting room.

Please note the following:
• Conference Center PCs run on Microsoft Office 2013 (Italian language).
• Please note that presentations in previous editions may not function properly. Files created with other software programs are required to be converted to Microsoft Office 2013.
• Presentations must be on either CD Rom or USB memory key.
• All filmed sequences and/or videos must be in the same Power Point folder and copied into the file before being included in the presentation.
• For films and videos, we recommend “.avi” and “mpeg” file extensions. It is also advisable to use common “codecs”.

UEMS AND ITALIAN CME Accreditation

UEMS – European Union of Medical Specialists

An application has been made to the EACCME® for CME accreditation of this event.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Attendance is monitored through a scanner device in order to check learner’s entrance/exit each day (The presence is a main requirement to obtain credits). Participants will receive their certificate of attendance once they have filled in the evaluation form. All the information will be sent by e-mail after the congress.
ITALIAN CME – Continuing Medical Education
The Congress has been accredited by the National Commission for Continuing Education with the educational objective: Clinical Documentation. Clinical Training-Assistance Diagnostics And Rehabilitation, Assistance Profiles – Care Profiles (3), for the following disciplinary areas:
Medical Surgeon (Disciplines: Rheumatology, Allergology and Clinical Immunology, Anatomic Pathology, Anaesthesia and Reanimation, Clinical Biochemistry, Cardiology, Dermatology and Venereology, Endocrinology, Clinical Pharmacology and Toxicology, Medical Genetics, Geriatrics, Food and Nutritional Hygiene, Respiratory Illnesses, Infectious Diseases, Metabolic Diseases and Diabetes, Sports Medicine, Physical Medicine and Rehabilitation, General Medicine, Internal Medicine, Legal Medicine, Thermal Medicine, Nephrology, Orthopaedics and Traumatology, Clinical Pathology, Paediatrics, Dietetics) ; Biologist; Dietician; Physiotherapist; General Nurses; Paediatric Nurses, for nr. 700 participants.

Participants exceeding or with different professions will not be entitled to credits. Credits will be recognized only upon presence at 90% of the scientific sessions.

CME credits: n. 4,2 – CME ID 93- 218832 – ed.1

CME Provider
AIM Education – Provider n. 93
Via G. Ripamonti, 129
20141 Milan, Italy
Tel. +39 02 56601.1
Fax +39 02 70048585

CME@aimgroup.eu
www.aimeducation.it
VENUE

Built in 1926 and designed for storing goods, the “Magazzini del Cotone” building is Porto Antico’s main structure. Renovated in 1992 by architect Renzo Piano, these spaces are confirmed as one of the most popular locations for conventions, conferences and all types of events. A mix of innovation and tradition.

Inside the Porto Antico (Old Harbour) is the “Magazzini del Cotone” Conference Centre at the sea level with ample spaces and all possible solutions for big international events. An Auditorium of 1,480 seats, divisible into two mirror like rooms seating 740 each and a central stage designed as a theatre structure, adjustable to different heights perfect also for musical performances.

Thirteen modular rooms (2780 seats) and 8,500 square meters of exhibition space: charming rooms with views of the sea that adapt themselves to diverse fittings. The Conference Centre, fitted with the most advanced audio and video equipment, combines the charm of old architecture and modern and cutting-edge functionality.
How to reach the Venue

Porto Antico di Genova - Centro Congressi
Calata Molo Vecchio 15
16128 Genoa – Italy
Tel. +39 010 2485626
www.centrocongressigenova.it

Entrance: Foyer Maestrale Module 10
Access to the bench of the Old Dock and the Autosilo
The nearest parking is Autosilo | “Calata Gadda”

From Airport
- Taxi: about Euro 15,00 (one way)
- Bus: 30 minutes with shuttle bus Volabus Euro 6,00 (stop Piazza De Ferrari). Than from Piazza De Ferrari: subway to St. Giorgio Stop and than 15-minute walk, direction Porto Antico.

From Train Station Genoa (Piazza Principe)
- 15-minute walk direction Porto Antico
- Bus: 10 minutes, line 1 or 9, from Marittima Principe F.S. to Piazza Caricamento Terminal
- Subway: 5 minutes direction Brignole, San Giorgio Stop

From Highway
Exit from Genoa Ovest and take speed city motorway direction; after 3 km exit at Genoa Porto Antico; at the end of the road continue 50 m. and turn right at 2nd intersection to access Porto Antico.
TAXI DISCOUNT RESERVED TO ATTENDEES
An exclusive taxi promotion program is reserved to attendees: members of Cooperativa Radio Taxi Genova apply fixed fares for prearranged routes to and from the conference center.

Routes and Fares

**Downtown** (€ 12)
Train stations Principe and Brignole and all downtown hotels.

**Western area** (€ 24)
Airport, Tower Genova Airport Hotel and all hotels in Genova Sestri and Pegli.

**Eastern area** (€ 24)
AC Hotel and all hotels in Genova Nervi.

Surcharges
Sunday & Public Holiday surcharge: € 2
Midnight Surcharge: € 2,50

For information: [www.5966.it](http://www.5966.it)
Onsite will be a person in charge to call your Taxi!

---

ORGANIZING SECRETARIAT

**AIM Group International – Milan Office**
Via G. Ripamonti, 129 – 20141 Milan, Italy
Ph. +39 02 566011 – Fax. +39 02 70048578 | [www.mediterraneanrheuma.com](http://www.mediterraneanrheuma.com)
General information, registration and abstract: [info@mediterraneanrheuma.com](mailto:info@mediterraneanrheuma.com)
Accommodation: [info.hotel@mediterraneanrheuma.com](mailto:info.hotel@mediterraneanrheuma.com)

**Secretariat and Registration Desk**
The organizing secretariat desk will be at the participants' disposal at the congress venue according to the following schedule:

- **Thursday 12 April 2018** 11.00 am – 19.00 pm
- **Friday 13 April 2018** 08.00 am – 19.00 pm
- **Saturday 14 April 2018** 08.00 am – 13.00 pm
**REGISTRATION**

<table>
<thead>
<tr>
<th>REGISTRATION FEES (All fees are 22% VAT included)</th>
<th>Within 12 March 2018</th>
<th>March 13 - April 3 2018 (online) Onsite from April 12, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegate</td>
<td>€ 470,00</td>
<td>€ 530,00</td>
</tr>
<tr>
<td>Students/Trainée*</td>
<td>€ 180,00</td>
<td>€ 210,00</td>
</tr>
<tr>
<td>Healthcare Professional**</td>
<td>€ 180,00</td>
<td>€ 210,00</td>
</tr>
<tr>
<td><strong>Patients</strong>*</td>
<td>€ 50,00</td>
<td>€ 50,00</td>
</tr>
<tr>
<td><strong>Young Rheumatologists (under 40) and EMEUNET Members</strong></td>
<td></td>
<td>Free Registration</td>
</tr>
</tbody>
</table>

* In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be sent to the organizing secretariat by e-mail or onsite.

**Nurses, physiotherapists and occupational therapists. A letter of confirmation of your status from the Head of Unit or Institute must accompany the formal registration form.

*** For Patient sessions on nutrition and healthcare (Patients, Family members of Patients, Patients Associations members). This fee provides for admission to Patient Sessions to be held on April 13-14 in Libeccio Room. No access to exhibition Area and Scientific Institutional Sessions

**** Free Registration ONLY for presenters of accepted Abstract belonging to these categories: Young Rheumatologists and Fellows (under 40) and EMEUNET Members.

Free registration must be accompanied with certification issued by affiliated Institution/Department

**Registration fees include:**

- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance (will be sent by e-mail)
- Access to the exhibition and poster area (no for Patients)
- Coffee breaks and lunch, as indicated in the program
- Abstract Book: issue of the Clinical and Experimental Rheumatology Journal

**Payments**

Payments onsite are possible in cash (in Euro) or by credit card (American Express, VISA, Eurocard/Master Card). Please note that due to the Italian Law, it is forbidden to transfer cash between different subjects for an amount exceeding € 3.000,00.
**Name Changes**

After March 12, 2018 sponsors who wish to make name changes will be charged of an handling fee of € 50,00 (VAT 22% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

**Cancellation Policy**

Notification of cancellation must be sent in writing to AIM Group International. Cancellations will be accepted until December 31, 2017 with a refund of all prepaid fees expect for a 30% administration charge. No refunds will be made for cancellations received after this date.

**HOTEL**

For hotel reservation in Genoa, please note that AIM ITALY has been appointed as Official Housing Bureau of the XVII Mediterranean Congress of Rheumatology. For further information and reservations regarding **Special Hotel Packages** please see next section: **CONGRESS DELEGATE PACKAGES**.

For any information and/or reservation please contact us at:

**AIM Italy**

Via Ripamonti 129 -20140 Milano  
Ph + 39 02 566011  
E mail: info.hotel@mediterraneanrheuma.com

---

**CONGRESS DELEGATE PACKAGES**

<table>
<thead>
<tr>
<th></th>
<th>Within 12 March 2018</th>
<th>From 12 March 2018 and onsite</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Package A</strong></td>
<td>€ 750,00</td>
<td>€ 850,00</td>
</tr>
<tr>
<td><strong>Package B</strong></td>
<td>€ 660,00</td>
<td>€ 720,00</td>
</tr>
</tbody>
</table>

*All packages include registration fee and city tax*

For Hotel reservation in Genoa, please note that AIM Group International has been appointed as Official Bureau of the XVII Mediterranean Congress.

**Package A includes:**
- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance
- Access to the exhibition and poster area
- Coffee breaks and lunches, as indicated in the program
- Hotel accommodation **4 stars** for 2 nights taxes included *(roulette formula)*

**Double Room:** available just on request  
(the difference in price and city tax for the accompanying person are not included, to be paid directly at the hotel)

**Extra night/s:** available just on request - Price per room per night is € 155,00  
(€ 2 City Tax per person and per day is not included, to be paid directly at the hotel)
**Package B includes:**
- Admission to the scientific sessions
- Congress bag with complete meeting materials
- Certificate of attendance
- Access to the exhibition and poster area
- Coffee breaks and lunches, as indicated in the program
- Hotel accommodation 3 stars for 2 nights taxes included (*roulette formula*)

**Double Room:** available just on request
(the difference in price and city tax for the accompanying person are not included, to be paid directly at the hotel)

**Extra night/s:** available just on request - Price per room per night is € 130,00
(€ 1 City Tax per person and per day is not included, to be paid directly at the hotel)

*The Organizing Secretariat  AIM ITALY will be at disposal to suggest special package solutions for Students/Trainée, Healthcare Professional and Patients.*
For any further information please contact AIM ITALY at:
ph. 0039 02 566011 e-mail  info.hotel@mediterraneanrheuma.com
NETWORKING EVENING - Friday, April 13 2018
The Welcome Dinner will take place in the beautiful Villa Lo Zerbino in Genoa, on Friday, 13 April 2018.

Registration Cost
Each ticket costs **85,00€** starting from an aperitif and followed by a full course dinner, seating around tables and surrounded by the beautiful and antique rooms. Registration is now open!

Venue
Villa Lo Zerbino
Passo dello Zerbino, 1 - 16122 Genoa

Parking Information
Villa Lo Zerbino is very close to Piazza Manin, in the high side of the city and well connected to the city center through the large Via Assarotti. Due to the high turnout, we highly recommend to arrange car pooling or to come by taxi as the area does not provide a sufficient number of parking spots and cannot accommodate this need.

Coming by car
From A7-A10-A12-A26, exit Genova Est Distance from Genova Est exit: 2,6 km (8 minutes by car)
Once you're out of the motorway, stay take the right and proceed straight on Via Bobbio. At the first cross (you can see a traffic light) stay on the right and take Via Montaldo on your right, proceed to the uphill for a couple of kilometers and take your right at the first rotunda. Now you're in Piazza Manin, turn around the square and proceed stright after the traffic light. Then turn right and you're in Passo dello Zerbino 1, when you'll find the entrance of the villa.
USEFUL INFORMATION

ADMISSION
Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunch when expected. What colour is your badge?

Participants: TRANSPARENT
Faculty: RED
Exhibitors: GREEN
Patients and Associations: BLUE
The reissue of the badge will cost € 15.00, both in case of forgetfulness and in case of loss.

LANGUAGE
The official language is English. English – Italian / Italian-English simultaneous translation will be provided only for the PATIENT SESSIONS (Libeccio Room - April 13th-14th)

ATTENDANCE CERTIFICATES
Attendance certificates will be sent by e-mail the last day of the Congress to all regularly registered participants.

Wi-Fi
Free Wi-Fi is available in the Congress area.
The network name is Centro_Congressi and each participant will have to enter the password MEDRHEUMA2018.

COFFEE BREAKS AND LUNCH
Coffee breaks will be offered in the exhibition area (Exhibition Area, floor 1) as follows:

- Thursday 12 16:40-17:10
- Friday 13 10.50-11.20 16.40 -17.10
- Saturday 14 10.50-11.20

A buffet lunch will be offered in the lunch area (Poster Area, Floor 1) as follows:
- Friday 13, 2018 13.00 -14.00

CLOAKROOM
Cloakroom and luggage storage facilities are available in the congress venue.

INSURANCE
Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.
NO-SMOKING
Smoking in the meeting area is not allowed.

MOBILE PHONES
Delegates are kindly requested to set their mobile phones on silent mode in the halls where scientific sessions are being held.

PRIVACY DISCLOSURE AND PUBLISHING OF IMAGES
Pursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorization of the event. Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any). The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data.

The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129, vat no. 00943621003, e-mail address info.aimcongress@aimgroup.eu.

With regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data controller.
KEY DATES

ABSTRACT

ABSTRACT SUBMISSION DEADLINE
15 December 2017
Due to many requests, the submission deadline has been extended to 18th December 2017

ABSTRACT NOTIFICATION
15 January 2018

REGISTRATION AND PACKAGES

EARLY REGISTRATION DEADLINE
15 December 2017

LATE REGISTRATION DEADLINE
12 March 2018

ON SITE REGISTRATION
From 12 March 2018 and onsite
Visit the Congress website
www.mediterraneanrheuma.com
and watch the video with the interview performed by the Congress Chairman
Prof. Maurizio Cutolo
On behalf of the Board of the Mediterranean Congress of Rheumatology and of the Italian Society of Rheumatology